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CHAPTER 1 
INTRODUCTION 

3 
1.1 History 
Tsji Pa, physician to the Chinese emperor Hoang Ti (2674-2575 B.C.), described the 
syndrome of jaundice with fatigue, arthralgia and malaise as related to diseases of the 
liver. At that t"1me the treatment varied from administering herbs to restoring the yin-
yang balance with acupuncture (1 }. 
Two thousand years later Hippocrates described the same syndrome and differentiated 
liver disease due to the abuse of wine, a fulminant form of hepatitis and a third form 
that rendered the patient immune after recovery. His therapy consisted of melikraton 
(made from honey) and venapuncture (2). 
In the same era liver disease in India was treated with herbs among which Phyllanthus 
amarus; this plant contains alkaloids, galactosamines and flavonoids, which are 
substances that have an antihepatotoxic and possibly an antiviral activity (3.4,5). 
In the previous century jaundice was described to a gastroduodenitis with a catarrhal 
obstruction to bile (Bamberger 1855, Virchow 1865). The first report of a parenteraUy 
transmitted outbreak of hepatitis appeared by the end of the 19th century in factory 
personnel after revaccination against smallpox (LUrman 1885). In 1937 epidemiologic 
data accumulated to substantiate the existence of an infectious form of hepatitis, with 
outbreaks in schools, hospitals and other institutions (Sergeant 1937, Lisney 1937, 
Barber 1937, Cullinan 1939). Until the sixties, the main treatment for hepatitis remained 
symptomatic with rest, a diet rich in carbohydrates, low in fat and free of alcohol 
combined with laxatives and ample fluid. For the prevention of liver dystrophy a bovine 
adrenal extract was advised (6). 
WaldenstrOm (1950) described a serious form of chronic hepatitis in young women with 
liver cirr'hosis, plasma cell infiltration of the liver and hypergammaglobulinemia. This 
disease was associated with high morbidity and mortality, and because of 
hypergammag!obulinemia and plasmacell infiltration in the liver, immunosuppressive 
therapy with prednisone seemed obvious (7}. The hypothesis of immunologic damage to 
the liver led to controlled, clinical studies evaluating the effect of immunosuppressive 
therapy. Treament with prednisone improved liver function and life expectancy in 
patients compared to untreated control patients (8,9, 1 0). The etiology of this 
immunologically induced hepatitis was unknown. 
1 .2.1 history of hepatitis B virology 
In 1967 2 forms of viral hepatitis were recognised; one type resembling the classical 
infectious hepatitis and the other type resembling serum hepatitis (11 ). After the 
discovery of australia antigen as the hepatitis B virus surface antigen (HBsAg, Blumberg 
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1965, 1967). hepatitis B was recognised as serum hepatitis. Thereafter, the hepatitis B 
virus (HBV) particles were discovered in patient serum (Dane 1 970) followed by the 
core antigen (HBcAg, Almeida 1971 }, HBV associated DNA polymerase activity (ONAp, 
Hirschman 1971). the 'e' antigen (HBeAg, Magnius 1972) and HBV DNA (Robinson 
1974). With the recognition of a virus as the causative agent for immunological liver 
damage, a more rational approach of treatment became possible and prednisone 
treatment appeared to be contra-indicated (12, 13, 14). The first treatment aiming at the 
viral origin of chronic hepatitis was leukocyte interferon UFN). lt lead to the 
disappearance of HBeAg and ONAp activity from serum in patients with chronic HBV 
infection and to a marked decrease of HBsAg titers (15}. 
HBV is now characterized as a DNA virus with a small, circular, partly double stranded 
genome. The genome consists of a long strand (l H strand) of about 3200 nucleotides 
and a short strand (S ( + l strand) of 50 - 100 % of the L (-) strand (15). The L (-} strand 
conta"1ns the complete coding capacity of the virus with four major open reading frames 
{ORF's): S, C, P and X. The l (-} strand RNA transcript codes for four proteins and via 
reverse transcriptase activity also serves as the virus pregenome, that functions as a 
template for new HBV DNA genome synthesis (17). ORF S codes for the protein of the 
viral envelope. HBsAg is a conformational antigen composed of three protein pairs 
which have a terminal part in common (18). The common part is encoded by the S 
gene, while a 55 amino acid part upstream is encoded by the preS2 region and a 108-
116 amino acid section by the preS1 gene. Each of these three proteins can be 
glycosylated in its S gene part, so six possible proteins can be found on gel 
electrophoresis. P24s and GP27s, GP33s and GP36s and GP39s and GP42s contain, 
respectively, the S gene product, the Sand preS2 gene products and both the S, preS2 
and preS1 gene products and their glycosylated derivatives. The C gene encodes the 
nucleocapsid protein and contains a preC and C region. The complete gene product is 
cleaved on the membrane of the endoplasmic reticulum into a part that is assembled in 
the nucleocapsid particle and a part that is secreted in the blood (HBeAg) (19). The ? 
gene has the largest ORF and encodes the HBV DNA polymerase that has a duel 
function; it can synthesize viral DNA by DNA and RNA dependent DNAp activity (1 6). 
The X gene product (HBxAg) is a small polypeptide of 145-154 amino acids with trans-
activating properties and a close association with HBsAg and HBcAg expression in liver 
sections (20). These findings and the relationship between HBxAg expression in the 
nucleus and dysplasia suggest a relation to viral replication and to the pathogenesis of 
primary hepatocellular carcinoma. 
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Figure 1. HBV replication cycle in hepatocytes. o HBsAg, ~ HBcAg, 8 DNA polymerase, 
Q core, Q DNA L (-) strand, •:.J DNA S ( +} strand, ~RNA. The following steps are 
outlined in the figure: 1 - receptor mediated virus entry, 2 - uncoating, 3 - endogenous DNAp 
synthetase activity resulting in covalently closed circular DNA (cccDNAL 4 - transcription by 
cellular RNAp, 5 - viral protein synthesis, 6 - reverse transcription by viral DNAp, 7 - virus 
assembly, 8- budding out. 
6 
1 .2.2 HBV replication cycle 
Figure 1 more specifically shows the steps in the HBV replication cycle. The cycle starts 
with virus entry into hepatocytes. Polymerised human albumin receptors on the 
hepatocyte membrane and viral surface are reported to play an important role in virus 
binding to the hepatocyte membrane (21 ,22). After entry into the hepatocyte, 
uncoating and transport to the cell nucleus takes place. The incomplete double strand of 
the viral genome is converted into a completed double strand DNA molecule (covalently 
closed circular DNA), which supercoiled structure forms the template for RNA 
production {23). Endogenous DNA dependent DNAp activity is responsible for the 
completion of the supercoiled DNA structure. Cellular RNA polymerase H then 
transcribes the L (-) strand into multiple forms of 2.1 kb and 3.5 kb messenger RNA's. 
The 2.1 kb mRNA encodes the preS2, S and X gene products and the 3.5 kb mRNA 
encodes all gene products and functions as a pregenome for new viral DNA synthesis in 
a 1 :1 ratio. A new L (-) strand is generated by reverse transcriptase activity (RT) of the 
viral DNAp with simultaneous degradation of the RNA pregenome. After degradation of 
the RNA pregenome an oligonucleotide remains that functions as a primer for the $( +) 
strand synthesis (17 ,24). At the endoplasmic reticulum the assembly of core particles 
starts {17) and after completion of the virus particle the progeny of new virus may bud 
out the hepatocyte and infect neighbouring cells. 
1 .2.3 treatment strategy for chronic hepatitis 8 
With the recognition of viral antigens, antibodies, HBV DNA and HBV DNAp it became 
possible to characterize a state of infection in which the virus is considered no longer as 
harmful to the host as in case of active replication. This state of virus latency is 
characterised by a low level of HBV DNA and the absence of HBeAg in serum and 
HBcAg in the liver. Virus latency is followed by disappearance of clinical symptoms and 
normalisation of biochemical and histological abnormalities (25,26). The goal of antiviral 
treatment therefore is the induction of virus latency. There are patients in the 
Mediterranean and the Far East that remain viraemic after HBe-seroconversion because 
they carry a virus that has a mutation in the pre-core gene, giving rise to a novel 
translational stop codon (27 ,28). This pre-core mutant causes a severe anti-HBe 
positive hepatitis for which the exact mechanism and geographical distribution remains 
unclear. Because of the insights in the serology of viral infection, the treatment of a 
chronic HBV infection can be directed at blocking of viral replication and immune 
enhancement. The evolution of antiviral treatment over the centuries has evolved from 
mainly symptomatic and partly rational to mainly rational and partly symptomatic. 
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Figure 2 shows three levels of possible intervention in case of a viral infection. Only anamnestic 
and physical diagnostic data can be used to monitor treatment at level 3. Treatment consisted 
of supportive and Symptomatic measures until the sixth decade of this century. The 
development of biochemistry allowed recognition of the mechanism of hepatocellular damage 
with a more rational approach of therapy directed against immunologic damage at level 2. 
Molecular biology with virus nucleic acid hybridization, radioimmunoassays for viral antigens and 
antibody detection, now allow rational and specific blocking at level 1. 
Treatment at level 1 in figure 1 directed at the viral targets as depicted in figure 2 has 
not yet been fuHy explored in present clinical studies. The treatment effects on the 
separate viral targets can't be assessed by routine clinical tests, but effects on viral 
antigen production and nucleic acid production are used to assess treatment effect on 
replication activity. Quantification of these parameters is essential to evaluate the effect 
of a treatment regime. The goal of treatment is to induce virus latency, usually 
characterized by absence of serum HBeAg. This dichotomous test result characterizes a 
patient as a responder only at the moment of HBe-seroconversion, usualty after 1 0 - 20 
weeks of antiviral treatment. Since it is of great clinical interest to identify patients as 
potential responders prior to HBe-seroconversion in order to make decisions about 
treatment modifications, monitoring during treatment is needed. Decrease of HBV DNA 
levels in the serum may indicate whether a patient is likely to respond to treatment. 
Since negative test results for serum HBV DNA with persistence of HBeAg frequently 
occur during treatment, HBV DNA is not an optimal test to monitor treatment for HBe-
seroconversion. Quantification of HBeAg serum levels (29) may be of additional value to 
monitor patients with chronic hepatitis type B during treatment. 
1.2.4 treatment of chronic hepatitis B 
Meta-analysis on current treatment regimens for chronic hepatitis B shows several 
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approaches with effict on HBe-seroconversion {30). Firstly a monotherapy with the 
nucleoside analogue adenine arabinoside monophosphate (ARA-AMPl or alpha-interferon 
(a-IFNl and secondly a combination therapy. Several types of combination therapy have 
been tried such as corticosteroid withdrawal and a-lFN and a-IFN combined with ARA-
AMP or acyclovir (ACV). 
ARA-AMP as nucleoside analogue interferes with nucleic acid synthesis. Viral DNAp 
activity is preferentially blocked over mammalian cell polymerases (31 ). Eight controlled 
studies with these drugs have been carried out. Administration during 1 0 to 56 days 
resulted in an increase of 0 to 42 percent of HBe-seroconversion compared to control 
patients. Odds ratio on all 8 studies is estimated at 2.37 (95% Cl 1.1 2-5.19). Since the 
95% Cl excludes an odds ratio of 1, ARA-AMP appears to be an effective drug for the 
treatment of chronic hepatitis B (30). 
Monotherapy with a-lFN is also widely used for chronic hepatitis B. In 1991 the drug 
has been licensed in the Netherlands for this indication. Viral targets for a-IFN treatment 
are viral protein synthesis and viral antigen expression on hepatocyte membranes. 
Diminished protein synthesis and enhanced HLA class 1 antigen expression leading to 
cytotoxicity result from a-lFN administration. Sixteen randomized controlled trials with 
a-lFN have been published. Treatment regimens varied from 3 to 4 months of treatment 
with doses of 2.5 to 10 MU every day or every other day. Meta analysis shows an 
increase in HBe-seroconversion rate compared to controls varying from 18 to 37 
percent. The odds ratio was 4.2 for the total of the 16 studies (95% Cl 2.48-7.37}. 
Since this odds ratio excludes 1, a-IFN is now established as an effective drug in the 
treatment of hepatitis 8 (28). Side effects of a-IFN therapy such as influenza-like 
symptoms, fatigue, general malaise and bone marrow toxicity occur in most patients. 
Influenza-like symptoms can be adequately suppressed by paracetamol or indomethacin 
administration which may improve patient compliance to a-JFN therapy (30). 
An important approach consists in the concept of combining drugs with different viral 
targets. A combination of corticosteroid withdrawal followed by either ARA-AMP or a-
lFN has been carried out. Prednisolone 40 to 60 mg daily tapered to zero over a period 
of 6 to 8 weeks was followed by either ARA-AMP or a-lFN in standard regimes. A 
combination therapy of nucleoside analogues (ARA-AMP and ACV) with a-lFN has also 
been tried out. The overall beneficial effect on HBe-seroconversion compared to control 
patients was comparable to monotherapy with either ARA-AMP or a-!FN. The odds ratio 
was estimated at 4.1 (95% Cl 1.67-10.61), indicating that up to now no additional 
effect of combination therapy compared to monotherapy (30). Whether this is due to 
smaller numbers in the former group or whether a more effective combination of 
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antivirals is needed remains to be established. 
Therefore, we investigated the effect of ACV and a-IFN combination therapy in a large, 
controlled study and established the antiviral effect of 2 other drugs in order to evaluate 
their possible additional value in a treatment regime with a-IFN. Firstly zidovudine was 
evaluated, since the drug inhibits the enzyme reverse transcriptase and in vitro activity 
against HBV DNAp (31). Secondly. Phyllanthus amarus was investigated since this herb 
has been described as an important inducer of HBs-seroconversion (32). 
1.3. 1 history of hepatitis C virology 
In 1975 the existence of a virus was postulated as a cause for post-transfusion 
hepatitis. Because no serological evidence for hepatitis A, hepatitis 8, cytomegalovirus 
or EpsteinwBarr virus could be found, it was called hepatitis nonwA,non-8 {33}. Further 
evidence for a viral agent causing post-transfusion hepatitis was found in sera of a 
patient with nonwA,nonwB hepatitis and in sera from two blood donors. These sera were 
inoculated in four chimpanzees who developed a raise in aminotransferase levels 2 - 4 
weeks after inoculation. Liver biopsy specimens showed evidence of hepatitis, but 
serological tests for hepatitis A, hepatitis 8, cytomegalovirus and Epstein-Barr virus 
remained negative (34). In 1989 a virus being responsible for most cases of post-
transfusion hepatitis was found by isolating a part of its genome (35). It appeared to be 
a small virus with a single stranded RNA genome and a resemblance to flaviviruses, to 
which the name hepatitis C virus (HCVJ was given. An antibody assay became rapidly 
avaible for routine serological examination (36). These antiHCV antibodies are helpful in 
diagnosing HCV infection. Development of antigen tests and RNA hybridisation tests 
however, are required to elucidate the viral replication cycle. 
1 .3.2 treatment strategy for chronic hepatitis C 
AlphawiFN treatment has been reported to have beneficial effects in chronic hepatitis C 
(see section 1.3.3) during administration and in some of the patients after interruption 
of therapy. This effect can either be due to the protective effect of aw!FN on 
hepatocytes or to the induction of virus latency or elimination of a cytotoxic virus. The 
fact that a persistent beneficial effect remains after stopping treatment in a part of the 
patients, indicates that induction of virus latency may be responsible for the therapeutic 
effect in these patients. Rational design of therapy for nonresponders to a-IFN is only 
possible when targets in the replication cycle of the virus can be recognised. Since 
flaviviruses belong to the family of togaviruses, the replication cycle of the togaviruses 
(37) may serve to form hypotheses on HCV replication and treatment strategy (fig 3). 
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1.3.3 treatment of chronic hepatitis C 
Several drugs have been investigated in the treatment of chronic hepatitis C. So far only 
a-tFN has proven to be an efficient drug. In 1985 short courses of acyclovir failed to 
have any beneficial effect on chronic non-A,non-8 hepatitis (38). In 1986 a pilot study 
was reported on ten patients treated with a-IFN 5 MU {n=7) or 1 MU (n=3) daily, sub-
cutaneously, graduatly tapered to 1 MU thrice weekly. [n eight patients alanine 
aminotransferase CAL T) levels fell within the first month, and normal or nearly normal 
levels were seen after 4 months of treatment. Interruption of treatment in 2 patients 
resulted in an immediate rebound of hepatitis activity, so treatment was reinstituted and 
continued for 1 year in all 8 patients. In 7 biopsies taken after 1 year, marked 
improvement of liver histology was found (39}. 
A significant effect of a-IFN on serum ALT levels was observed in three randomized 
controlled studies (40,41 ,42). ALT normalisation occurred in approximately 50 % of 
patients with doses of 2 - 5 MU thrice weekly during 2 - 6 months. Improvement of 
ALT levels was accompanied by histological improvement in these studies. In over 50 
% of responders to therapy positive results were only transient and rebound of 
aminotransferase levels to pretreatment level occured. Clearly no eradication of virus 
was achieved in these patients and more specific tests for viral replication activity such 
as RNA detection or liver immunofluorescence for HCV antigen are needed to assess 
endpoints and efficacy of antiviral therapy. Beta-interferon has also been reported to 
suppress AL T levels in chronic non-A,non-8 hepatitis, but results are not superior to a-
interferon and since the drug has to be administered intravenously, it is not the 
preferable drug (43,44). lnterleukin-2 has been given intravenously in a dose of 
100.000 IU/kg three times a week, but severe side-effects in two patients necessitated 
discontinuation of the scheduled three months course (45). 
The cornerstone of therapy for chronic hepatitis C appears to be a-IFN, although the 
majority of patients appear to be partial or nonresponders to a-IFN. A case is presented 
of chronic active hepatitis due to HCV infection with a sustained remission after a-JFN 
therapy despite HIV coinfection with active virus replication. Furthermore, since 
togaviruses require human transfer RNA fragments and a viral RNA dependent RNA 
polymerase activity for initiation of replication {fig 3), we investigated the effect of the 
DNA dependent RNA polymerase inhibitor rifampicin in a partial responder to a-lFN 
therapy. 
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1.4.1 history of hepatitis D virology 
Since the discovery of the delta agent by Rizzetto in 1977 (46), the defective RNA virus 
has been found to be a spherical particle of 36 nm coated with HBsAg (47). The 
genome (HDV RNA) is a circular single stranded RNA molecule of (-) polarity (48). It has 
the ability to form an unbranched rod structure by folding itself through base pairing like 
several satellite plant viruses (49,50). HDV RNA contains at least 5 ORF's on its 
genomic and antigenomic strands (51). ORF 5 on the antigenomic strand is predicted to 
encode 2 major species of delta antigen (HDAgl {51). HDV genome replication is 
consistent with a rolling circle model producing antigenomic strands (mRNA's) through 
self cleavage and ligation in the absence of proteins (52, fig 4). 
1.4.2 treatment stragegy for hepatitis D 
Evidence has accumulated that little direct interaction between the virus and the host's 
immune system occurs. The presence of immune reactive cells in the liver as well as 
presence of HDAg in serum early during infection makes sensitization to HDAg possible. 
However, since virus particles in serum are enveloped by HBsAg and HDAg is not 
expressed on hepatocyte membranes, the significance of host immune reactivity in 
relation to immunologic clearance of the virus appears low. The role of HBV in the 
replication cycle of HDV is limited to virus entry or release from host cells (53); therapy 
should be directed to either interference with virus replication or towards elimination of 
HBV (development of antiHBs). HDAg is essential for replication of the viral genome 
(53) and specific targets for therapy directed to HDV infection are therefore an 
inhibition of HDAg synthesis, an inhibition of cellular RNA polymerase, a blocking of 
uncoating or assembly of the virus and a clearance of HBsAg (fig 4). 
1.4.3 treatment of hepatitis D 
There is no established therapy for chronic HDV infection. Immune suppressive therapy 
with corticosteroids or azathioprine did not ameliorate the course of the infection (54), 
nor did levamisole (55). However, a 3 to 12 month course of a·interferon has been 
reported to inhibit HDV replication. HDAg in the liver and serum diminishes or 
disappears, HDV RNA in serum disappears and AST levels drop. But on stopping 
treatment, evidence of HDV replication reappeared with elevation of serum AST levels 
(56-61). For liver transplantation in case of end-stage liver disease due to HDV 
infection, excellent graft survival has been reported and 2 out of 7 patients cleared HDV 
as well as HBV infection (62). HBs-seroconversion has been reported during a·IFN 
therapy in chronic hepatitis B and the combination of a-IFN and ACV was found to 
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circular HBV DNA (cccDNA). Steps of the replication cycle: 1 - receptor mediated virus entry, 
2 - uncoating, 3 - rolling circle method of RNA ... production resulting in generation of multimeres 
of antigenomic RNA, 4 - selfcleaving of multi me ric structure in monomeric RNA .. , 5 - selfligation 
of anti genomic RNA, 6 - rolling circle method of RNA· production resulting in multimeric copies, 
7 - selfcleaving of RNA·· 8 - selfligation of RNA·· 9 - viral protein synthesis, 10 - transcription of 
HBV DNA mANA, 11 - HBsAg synthesis, 12- virus assembly. 
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induce HBV virus latency in 40 % of treated patients (29). Since clearance of HBV 
results in clearance of HDV infection, we evaluated the effect of combination of a-IFN 
and ACV treatment in patients with a chronic hepatitis D infection. 
1.5 aims of the study 
Hepatitis 8: 
Hepatitis C: 
Hepatitis 0: 
-evaluating the effect of acyclovir, zidovudine and 
Phyllanthus amarus on HBV replication in order to 
improve current treatment regimes concerning 
H Be-seroconversi on 
-defining quantitative HBeAg and HBV DNA analysis as 
parameters to monitor antiviral treatment 
- investigating the influence of indomethacin and 
paracetamol on the antiviral effect of a-IFN 
-evaluating the effect of rifampicin in addition to 
a-IFN treatment in a partial responder to a-IFN 
therapy 
- documenting that chronic hepatitis C complicated 
by coinfection with HIV can mimic autoimmune type 
chronic hepatitis and that antiviral therapy can 
lead to sustained remission of of hepatitis C. 
-evaluating the effect of treatment with a-IFN 
and ACV on chronic hepatitis D 
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CHAPTER 2 
FAilURE OF ACYClOVIR TO ENHANCE THE ANTIVIRAl EFFECT OF AlPHA 
l YMPHOBLASTOID INTERFERON ON HBe-SEROCONVERSION IN CHRONIC HEPATITIS 
B. 
A multi-centre randomized controlled trial. 
The contents of this chapter have been accepted for publication in The Journal of 
Hepatology 1991, under the same title and with the following authors: lucas Berk, 
So!ko W Schalm, Robert A de Man, Rudolf A Heytink, Pierre Berthelot, Christian 
Brechot, Bernard Boboc, Fran<;oise Degas, Patrick Marce!lin, Jean-Pierre Benhamou, 
Georg Hess, Siegbert Rosso!, Karl-Hermann Meyer zum Buschenfelde, Robert AFM 
Chamuleau, Peter LM Jansen, Henk W Reesink, Beat Meyer, Christoph Beglinger, Georg 
A Stalder, Jannie W den Ouden-Muller and Maurits de Jong. 
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SUMMARY. 
Serum HBeAg levels and HBe-seroconversion were investigated in patients with chronic 
HBeAg positive hepatitis who were randomized to receive either alpha lymphoblastoid 
interferon {5 megaunits subcutaneously daily for 1 6 weeks) plus acyclovir {2 grams 
intravenously daily during weeks 1 +2 and weeks 9+10) {n=49l or no treatment 
(n =48). HBeAg levels in serial dilutions of patient serum were assessed quantitatively 
by radioimmunoassay and compared with the values found for negative control serum. 
One year after the start of therapy 44 treated patients and 43 control patients were 
available for follow-up. A complete response (HBe-seroconversion) occurred in 11 
treated patients (25%) and 6 controls (14%) (difference: 11 %, 95% Cl -5 - 28%). A 
partial response (HBeAg < 50% of initial leve!) was found significantly more often for 
treated patients (n=13, 30%1 than for controls (n=2, 5%) (difference: 25%, 95% Ct 
10 - 40%). During acyclovir-interferon combination therapy the decrease in HBeAg level 
was similar to that achieved during therapy with interferon alone. We conclude that 
acyctovir does not enhance the effect of interferon on serum HBeAg levels. Since 
HBeAg levels continue to decline during interferon treatment and rebound thereafter to 
pretreatment levels, prolongation of therapy may yield a higher response rate. 
Keywords: chronic hepatitis 8, combination therapy, quantitative HBeAg analysis, 
interferon 
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INTRODUCTION. 
Chronic hepatitis 8 virus {H8V) infection is associated with an annual mortality rate of 
more than a million patients. Decompensated cirrhosis of the liver and hepatocellular 
carcinoma account for the majority of the losses (1 ,2). Progression to this end-stage of 
disease appears to be related to active viral replication (3.4) and is, in Northwestern 
European patients, almost invariably associated with HBeAg positivity (5). HBe-
seroconversion is associated with inactivation of clinical, biochemical and histological 
signs of disease {3,.4). ln 10 controlled trials to evaluate the effect of alpha interferon 
(lFNl therapy on HBe-seroconversion, the response rate for treated patients was about 
15% higher than the spontaneous rate found for control patients (6). In a small 
controlled trial using the combination IFN and descyclovir (DACV), the oral prodrug of 
acyclovir (ACV), 7 out of 18 treated patients (40%) exhibited HBe-seroconversion 
versus none of the 18 controls (7). Because this combination therapy appeared more 
effective than monotherapy with IFN, we designed a large controlled trial to test 
whether HBe-seroconversion after lFN and ACV combination therapy was at least 40% 
more frequent than with no treatment. 
In order to determine the effect of additional ACV therapy, we measured HBeAg 
quantitatively and compared decrease of HBeAg during lFN plus ACV with that during 
iFN monotherapy. 
METHODS. 
Patients. 
Ninety-seven patients entered this study from 7 different hospitals in northwestern 
Europe: Oijkzigt, Rotterdam; Laennec, Paris; Beau jon, Paris; 1" Medizinische Klinik und 
Poliklinik, Mainz; Academic Medical Centre, Amsterdam; Kantonspita!, Basel; Sint 
Franciscus Gasthuis , Rotterdam. The study protocol was approved by aH human study 
committees of the participating centres and patients gave written informed consent 
prior to entry. Inclusion criteria were: indications for therapy (symptoms or progressive 
liver disease); chronicity, documented by HBsAg positivity for more than one year or 
histological evidence of chronic disease; stable HBV replication, as indicted by the levels 
of serum HBeAg and serum HBV DNA or HBV DNA polymerase activity on 2 occassions 
for six months prior to entry or expression of HBcAg on more than 5% of hepatocytes 
with stable HBeAg level on 2 occassions. Exclusion criteria were: active hepatotropic 
viral infections other than HBV (HDV, CMV, EBV, HAV, non-A,non-8); impaired immune 
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reactivity (transplant and dialysis patients, CD4 positive cell counts less than 400/mm3 ; 
antiviral or immune modulatory treatment in the past 6 months; recent alcohol or drug 
addiction; decompensated liver disease (ascites, encephalopathy, variceal bleeding); any 
severe disease affecting the candidate's prognosis. 
Randomization. 
Patients were enrolled in the study after central assessment of their virological eligibility 
in Rotterdam. They were centrally randomized in blocks of 6 patients per centre, using a 
table with random numbers and numbered sealed opaque envelopes (8). The total 
number of patients to be included in the study was estimated to be between 80 and 
100 with an expected HBe-seroconversion rate of at least 50% for the therapy group. 
After randomization there were forty-nine patients in the therapy group and 48 in the 
control group. During the last months of enrollment, incomplete blocks of 6 patients 
were completed without considering the participating centre (9). 
Treatment. 
Patients in the therapy group received alpha !ymphob!astoid interferon {[FN, Wellferon, 
Beckenham, UK) (5 111ega-units daily subcutaneously for 1 6 weeks) and two 2-week 
courses of acyclovir {ACV) (2 g daily intravenously) during week 1 and 2 and during 
week S and 10 of IFN administration. ACV administration required hospitalisation. 
During the first hospital stay, instruction on the lFN injection technique was given so 
that patients could se!f-administer the drug. ACV (1 g ACV dissolved in 1000 ml saline) 
was given twice daily intravenous!y in 1 hour. Daily urinary output was kept at at least 
2000 mi. During the first 3 days of lFN administration, slow release indomethacin (2 x 
75 mg daily} or paracetamol (4 x 500 mg daily) was given orally to reduce initial side-
effects. Patients in the control group received no treatment for 52 weeks. 
laboratory determinations. 
Serum samples were taken weekly during treatment and every four weeks during 
follow-up in the therapy group and every four weeks in the control group. Quantitative 
assessment of HBeAg (R.J.A., Abbott, IlL) was carried out centra!ly at the Rotterdam 
hepatitis laboratory (Department of Virology, Erasmus University Rotterdam). Pre-entry 
serum was tested undiluted and diluted 5, 25, 125 and 625 times. The test results 
were expressed as the p/n ratio, i.e. the ratio of the counts at the dilution tested and in 
a negative control serum sample. The highest dilution, with an initial p/n ratio of 1 0 to 
15, was used to observe drops in HBeAg level throughout the study. When indicated, 
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undiluted serum was also tested to confirm the event of HBe-seroconversion. Serum 
HBV DNA levels were tested by liquid phase hybridization with a 1-125 labeled probe 
{Genostics, Abbott, Ill.). Aspartate aminotransferase (ASTJ levels were tested routinely 
(SMAC, Technicon, NY). 
Response. 
HBe-seroconversion {complete response) was defined as a negative HBeAg test on two 
successive occasions during the 52 weeks of follow-up. Patients with a decrease in 
HBeAg p/n ratio of more than 50% on two successive occasions during follow-up are 
defined as partial responders. Nonresponders did not exhibit a marked decrease in 
HBeAg ( < 50 %) during follow-up. 
Statistics. 
Entry data, plotted in histograms to assess the skewness of distribution, showed that 
medians had to be used for data presentation. Medians of data collected on the basis of 
intention-to-treat (raw datal were not different from medians of data corrected for 
patients lost to follow-up (clean data). Clean data are presented in this report. Data 
were calculated at 2-week intervals during treatment, while blood sampling was 
performed weekly. As a result, samples missing during treatment could be replaced with 
the previous blood sample. Two-sample Wilcoxon rank sum analysis was used to 
compare different groups and the Wilcoxon matched sample sign test to evaluate data 
within a group during follow-up. Differences between two curves were assessed by log 
rank testing. 
RESULTS. 
Balance of randomization. 
Randomization resulted in a balanced distribution of sexes, age, AST level, HBV DNA 
positives, antiHIV positives, cirrhotics and initial serum HBeAg levels between the 
therapy and control groups (table 1 ). Chronicity was documented in 83 patients by 
HBsAg positivity for more than 1 year; in 14 patients with a more recent detection of 
HBsAg positivity, a liver biopsy provided evidence of chronic disease. One patient died 
of a myocardial infarction before entry, 2 patients withdrew from the treatment protocol 
at 4 and 8 weeks, respectively, because of side-effects and 7 patients were lost to 
follow-up. At 52 weeks 44 patients of the therapy group, who had completed 16 
weeks of treatment, and 43 patients from the control group were available for follow-
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up. Serum samples for quantitative HBeAg analysis at key-point time intervals (weeks 
0, 16, 32 and 52) had been obtained from 79 to 98% of control patients and 82 to 
100% of treated patients. 
table 1. 
PATIENT CHARACTERISTICS AT ENTRY 
therapy group control group 
entered (n) 49 48 
lost to follow-up (n) 5 5 
female/male 5/44 6/43 
age, median/range (y) 34.5 (22-69) 35 (19-62) 
antiHIV, + ve (n) 3/43 5/43 
antiHCV, + ve (n) 1/44 0/43 
cirrhosis {n) 2/37 3/34 
AST, median/range (U/1) •• 49 (11-515) 48 (22-412) 
HBV DNA, + ve {n) 49 48 
HBeAg, serum dilution . 
undiluted (nl 3 4 
5x 5 2 
25 X 10 13 
125 X 25 24 
625 X 0 
• serum dilution to obtain a p/n ratio of 10 -15 (see methods, laboratory determinations} 
•• normal value < 30 U/1 
Qualitative HBeAg analysis. 
HBeAg seroconversion occurred in 11 out of 44 {25%, 95% CJ 12 - 38%) treated 
patients and 6 out of 43 {14%, 95% Cl 7 - 21 %) control patients {fig 1, no significant 
difference between treatment and control groups). !n addition to a complete response, a 
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partial response was observed in 13 out of 44 (30%, 95% Ci 17 - 45%) treated 
patients versus 2 out of 43 (5%, 95% Cl 1 - 16%) control patients. The difference in 
partial response between the treated and control groups was 25% (95% Cl 10- 40%); 
this is statistically significant since zero is not included in the confidence interval. 
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fig 1. Cumulative percentage of patients with HBe-seroconversion in the therapy group versus 
spontaneous HBe-seroconversion in the control group. 
Quantitative HBeAg analysis. 
For treated patients quantitative HBeAg assessment showed a marked decrease 12 
{38%) and 16 weeks {49%) after initiation of treatment compared to the pretreatment 
level (p = 0.0001, fig 2b). A significant difference in the decrease in HBeAg between 
the treated group and the control group occurred at 12 weeks and persisted at 16 
weeks (p = 0.003 and p = 0.0003); however at 32 and 52 weeks no significant 
difference was observed. Within the treatment group three types of responses were 
observed {fig 2b). Complete responders were HBeAg negative in the fixed serum dilution 
at a median of 1 2 weeks of treatment; partial responders showed a marked decrease in 
HBeAg level but were on average not negative at 1 6 weeks. Nonresponders showed 
little variation in HBeAg level. When treatment was interrupted, a rebound to 
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fig 2. Decrease in median HBeAg level in the therapy group resulted in a statistica[[y significant 
reduction of HBeAg level at 12- 16 weeks of treatment; the difference in HBeAg level with the 
control group became statistically significant at 12 weeks (fig 2~, see results, quantitative 
HBeAg analysis). Median HBeAg p/n ratio for responders, partial responders and nonresponders 
in the therapy group, reveals a decrease for the first 2 groups with a persistent low HBeAg level 
in responders and a rebound to pretreatment levels in partial responders (fig 2bJ. 
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pretreatment levels occurred in the partial responders. No cases of reactivation were 
observed among responders throughout the follow-up period. 
Combination therapy versus monotherapy. 
The decrease in HSeAg level per 2 weeks of therapy was evaluated separately for 
monotherapy (IFN) and combination therapy {IFN + ACV). For every patient from the 
therapy group, the 1 6-week treatment period was divided in two 2-week periods during 
which combination therapy was given and six 2-week periods during which 
monotherapy was given. For every 2-week period the decrease in HBeAg level was 
calculated and expressed as percentage of the HBeAg level at the beginning of that 2-
week period. Median percentual decrease per 2-week treatment period is presented in 
tabel 2. No additional decrease in HBeAg level could be related to ACV therapy. 
Biochemical response. 
Pretreatment AST level in responders appeared higher than in partial responders and 
nonresponders, but no statistically significant differences were observed. The median 
levels with 95 % Cl respectively were: 65 150-2381, 53 137-791 and 48 136-661 un. 
Serum AST !eve! normalized in 10 out of 11 responders at week 52 (median 25 U/1, 
95% Cl 16-39 U/1. p =0.001 6). In partial responders and nonresponders no significant 
decrease occurred, at week 52 serum levels respectively were 49 U/1 (95% Cl 1 9-90) 
and 38 U/1 195% Cl 27-621 
Side effects. 
Symptoms, either related to chronic hepatitis B or treatment with IFN and ACV, were 
reported by 43 out of 44 therapy patients and by 27 out of 43 control patients. Fatigue 
was reported by 32 therapy patients and 8 control patients. Myalgia, hairless, anorexia, 
arthralgia and headache respectively occcurred in 12, 12, 8, 6 and 6 therapy patients, 
but only incidentally in the control patients. Fever shortly after initiation of lFN 
treatment was reported by 1 2 patients. Neurotoxic symptoms due to IFN occurred in 4 
patients of whom 1 had a seizure at 10 weeks after onset of IFN treatment. In 29 
patients leucopenia was found during therapy with white blood counts under 3.0 x 109 
cells/1. Dose reduction due to side effects was required in 17 patients. Administration of 
ACV caused frequent episodes of phlebitis at the site of canulation. Symptoms of 
fatigue and diminished performance were not comparable with the period of lFN 
monotherapy because of hospitalization during ACV administration. Diminished renal 
function due to ACV was not observed. Nor were any neurotoxic effects observed due 
to ACV administration. 
table 2. 
THE MEDIAN PERCENTAGE DECREASE IN HBeAg FOR EACH 2-WEEK PERIOD OF 
TREATMENT TO DETERMINE THE ADDITIONAL EFFECT OF ACV 
period therapy HBeAg decrease 
{week) {%) 
0- 2 IFN + ACV -1.2 
2- 4 IFN 8.5 
4- 6 IFN 4.8 
6- 8 IFN 8.1 
8- 10 IFN + ACV 8.3 
10- 12 IFN 8.3 
12- 14 IFN 8.7 
14- 16 IFN 6.8 
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The decrease in HBeAg level at the end of each 2·week period during treatment is expressed as 
a percentage of the HBeAg level at the beginning of that 2·week period. Decrease HBeAg = 
((HBeAgw...,k" • HBeAgwook n+::..)/ HBeAgw.,.,l< nl x 100. Median levels are presented in the tabel. No 
additional decrease was observed during combination treatment (week 0-2 and week 8- 10). 
DISCUSSION. 
An additional effect of ACV on HBe-seroconversion during IFN treatment was indicated 
in a pilot study (1 OJ and a small controlled study {7). The present large controlled study 
failed to cause an additional beneficial effect of ACV on HBe-seroconversion in chronic 
hepatitis B. At the start of the study it was stated that combination therapy would be 
considered worthwhile for our patient population if a HBe-seroconversion rate of more 
than 50% was obtained. This result was not observed. The marked difference with 
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respect to the previously mentioned pilot study may be due to patient selection in an 
uncontrolled setting. Meta-analysis of 16 randomized controlled trials with alpha 
interferon showed only a modest benefit for alpha interferon (odds ratio 4.2, 95 % Cl 
2.48 - 7 .37) compared to no treatment (11 ). Modification of usual 12 - 16 week lFN 
treatment regimens is therefore necessary. Following advise of our statistician, we 
assessed the therapeutic effect of IFN on a single endpoint, the HBeAg level, while 
other studies also used HBV DNA, HBV DNA polymerase activity and HSsAg as 
endpoints. When several markers are used, positive results are more easily obtained. 
HBe-seroconversion was choosen as single endpoint because of the great clinical 
implications of this event for patients with a chronic hepatitis 8 infection {3,4). 
Therefore, changes in HBeAg level were more indicative for response to treatment than 
changes in HBV DNA level. HBV replication activity monitored by serum HBV DNA 
hybridization is used by many investigators as endpoint. A disadvantage of the HBV 
DNA assay is that the detection limit varies considerably. Furthermore, the HBV DNA 
level will decline below the detection limit before a situation of virus latency will be 
obtained. Therefore HBV DNA testing, although of great importance for monitoring 
effects of antiviral agents, may not be the test-of-choice for assessment of an endpoint 
of therapy. Quantitative HBeAg analysis as performed in this study, appeared a very 
usefull test to determine response to treatment, as indicative for HBe-seroconversion. 
Because of the short halflife of the serum level of HBeAg, this test appeared also useful! 
to evaluate the decline per two week period during either lFN or IFN plus ACV 
treatment. 
The concept of a partial response to treatment is often used to indicate patients who 
become negative for HBV DNA while remaining positive for HBeAg. Quantitative serum 
HBeAg analysis leads to a different concept of partial response. A marked reduction of 
HBeAg level is clearly related to iFN therapy, as shown in this study, while a steady 
decrease in HBeAg level during treatment suggests that prolongation of treatment might 
yield more responders. 
We conclude that 16 weeks of IFN {5 MU daily subcutaneously) plus two 2-week 
courses of ACV (2 g daily intravenously) result in HBeAg seroconversion in 25 percent 
of patients. No additional benefit of adding ACV to IFN treatment was observed. 
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CHAPTER 3 
COMPLEMENTARY QUANTITATIVE HBeAg MONITORING OURING ANTIVIRAL 
THERAPY FOR CHRONIC HEPATITIS B 
The contents of this chapter have been submitted for publication to Hepatology under 
the same title and with the following authors: Luuk Berk, Harry LA Janssen, Robert A 
de Man, So!ko W Schalm and Rudolf A Heijtink. 
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SUMMARY 
Markers of viral replication, such as HBeAg and HBV DNA, are used to monitor 
treatment of chronic hepaf1f1s B. To quantify hepatitis B virus replication, serum HBV 
DNA levels are usually assessed; however, it is uncertain how accurately a negative 
serum HBV DNA predicts response to therapy. Since in most cases the serum HBeAg 
level reflects HBcAg production in the liver, a quantitative assay for HBeAg might also 
be suitable for monitoring therapeutic effects. We determined the HBeAg levels 
quantitatively and compared them with the results of HBV DNA analysis found for 44 
patients with chronic HBeAg-positive hepatitis who received alpha lymphoblastoid 
interferon for 1 6 weeks. 
HBe-seroconversion (HBeAg~response) occurred in 11 out of 44 patients with a 
sustained response during fo!low-up; 13 patients showed a decrease of > 50 % of the 
initial HBeAg level (partial HBeAg~response); 20 patients {HBeAg-nonresponders) did not 
exhibit a significant decrease in HBeAg level. HBV DNA became negative in 17 out of 
44 patients, but 6 patients again had positive HBV DNA levels before the end of the 
study. Serum HBV DNA levels decreased significantly during therapy in HBeAg~ 
responders {p=0.03) and partial HBeAg~responders (p<0.001) as well as HBeAg~ 
nonresponders {p =0.001 ). 
We conclude that HBe~seroconversion is of more prognostic significance than HBV DNA 
negativity. A quantitative HBeAg assay can be used for both monitoring and endpoint 
determination of antiviral therapy and is ~ in most cases - sufficient as single parameter 
until HBe~seroconversion. Additional HBV DNA monitoring may identify potential 
responders as a subgroup of patients with high initial reptication activity. 
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INTRODUCTION 
Definition of the stage of a chronic hepatitis 8 virus (HBV) infection requires the 
assessment of several markers of disease. Clinical, biochemical, virological and his-
tological measurements have to be made since they determine the prognosis for and 
management of a patient. However, for monitoring antiviral therapy, virological 
measurements are the most important since induction of virus latency is the aim of 
treatment. Serum HBeAg positivity is associated with ongoing viral replication and HBe-
seroconversion is generally considered to be an important event that indicates a state of 
virus latency in patients with wild type HBV infection (1 ,2,3). A standard quantitative 
test for HBeAg is not available. Therefore, the serum HBV DNA level is used to quantify 
hepatitis B virus {HBV) replication activity. We compared the values of a standard HSV 
DNA test with an in house quantitative serum HBeAg assay during antiviral combination 
treatment with alpha iymphoblastoid interferon (IFN). 
MATERIALS AND METHODS 
Patients. 
The effect of IFN and acyclovir (ACV) combination therapy was investigated in a 
controlled trial (4). We compared the HBeAg and HBV DNA analyses of the 44 patients 
who were randomized to the treatment group. Inclusion and exclusion criteria are 
described elswhere (4). Patients received 5 mega-units of alpha lymphoblastoid 
interferon (IFN, Wellferon, Beckenham, UK) daily subcutaneously for 16 weeks and two 
2-week courses of acyclovir (ACV} (2 g daily intravenously), as described previouSly (4). 
No effect of ACV was demonstrated, so patients are considered to have received only 
lFN as effective therapy. 
Laboratory determinations. 
Serum samples were taken weekly during treatment and every four weeks during 
follow-up. Quantitative assessment of HBeAg (R.!.A., Abbott, Ill.) was carried out 
centrally at the Rotterdam hepatitis laboratory {Department of Virology, Erasmus 
University Rotterdam). Pre-entry serum was tested undiluted and diluted 5, 25, 125 and 
625 times. The test results were expressed as the p/n ratio, i.e. the ratio of the counts 
at the dilution tested to the mean of 5 negative control serum samples. The cut-off was 
the mean of 5 negative control samples plus three standard deviations. The highest 
dilution, with an initial p/n ratio of 10 to 15, Was used to monitor the HBeAg level 
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throughout the study. When indicated, undiluted serum was also tested to confirm HBe-
seroconversion. Serum HBV DNA levels were determined by means of a liquid phase 
hybridization assay with an 1-125 labeled probe (Genostics, Abbott, 111.). 
Response terminology. 
An HBeAg response was defined as a negative HBeAg test result for undiluted serum 
samples on two successive occasions during the 52 weeks of follow-up. A partial 
HBeAg response was defined as a decrease in the HBeAg p/n ratio of more than 50% 
that persisted on two successive occasions; this differs from the usual definition of HBV 
DNA levels below 1 pg/ml with persisting HBeAg. HBeAg-nonresponders did not exhibit 
a marked decrease in HBeAg ( < 50%}. 
Statistics. 
Entry data, plotted in histograms to assess the skewness of distribution, showed that 
medians had to be used for data presentation. Medians of data collected on the basis of 
intention-to-treat (raw datal were not different from medians of data corrected for 
patients lost to follow-up (clean datal. Clean data are presented in this report. The 
Wilcoxon matched sample sign test was used for comparison of data before, during and 
after treatment. The two-sample Wilcoxon rank sum ana[ysis was applied to compare 
different groups. 
RESULTS 
Qualitative analysis. 
HBeAg seroconversion occurred in 11 out of 44 (25%, 95% Cl 12-38) patients who 
remained HBeAg-negative throughout the follow-up period of 52 weeks. HBV DNA 
negativity occurred in 17 out of 44 patients after entry to the study (39%, 95% Cl 24-
53, table 1} ; 2 patients became HBV DNA-negative in the 4-week period between entry 
and the start of treatment. For 8 out of 10 responders serum HBV DNA was negative 
prior to HBe-seroconversion; in 1 patient serum HBV DNA disappeared at the time of 
HBe-seroconversion; in another patient HBV DNA persisted at row levels for 25 weeks 
after HBe-seroconversion. In 1 HBeAg-responder HBV DNA could not be tested before 
HBe-seroconversion. Of the 17 patients who became serum HBV DNA-negative, only 11 
were still negative at 52 weeks. One patient was negative for HBeAg at 52 weeks and 
positive for HBV DNA; reactivation occurred shortly afterwards. 
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table 1: Qualitative changes in serum HSeAg and HBV DNA status 
HBeAg negative {n) HBV DNA negative (n) 
total (n =44) total (n=441 responders 
In= 111 
week -4 0/44 0/44 0/11 
weekO 0/44 2/42 2/11 
week 16 4/44 13/44 8/11 
week 32 8/44 11/42 9/11 
week 52 11/44 11/44 10/11 
Quantitative analysis. 
Quantitative HBeAg assessment showed a marked decrease 12 {38%) and 16 weeks 
(49%) after initiation of treatment compared to the pretreatment level {p < 0.001, fig 
1). Three subgroups of patients were recognized on the basis of the HBeAg levels (fig 
2); For HBeAg-responders (n = 11) the fixed serum dilution was HBeAg-negative after a 
median of 12 weeks of treatment; partial HBeAg-responders {n = 13, 30%, 95% Cl 16-
43) showed a marked decrease in HBeAg level but were not negative at 16 weeks; 
HBeAg-nonresponders (n = 20) showed little variation in HBeAg level. When treatment 
was interrupted, a rebound to pretreatment levels occurred in the partial responders. No 
reactivation was observed among the responders within the 52 weeks of followMup. 
Serum HBV DNA decreased from a median level of 103 pg/ml at week 0 to 13 and 6.5 
pg/ml at weeks 8 and 1 6, respectively (p < 0.001 ). After termination of treatment a 
rebound to 82.5 pg/ml occurred at week 52, a level which was no longer significantly 
different from the pretreatment value (fig 2a). Subgroup analysis of HBeAg-responders, 
partial HBeAgMresponders and HBeAg-nonresponders showed a significant decrease in 
HBV DNA in all groups after 16 weeks of treatment. The median HBV DNA level for 
HBeAg-responders decreased from 18.5 pg/ml at week 0 to under the detection limit at 
week 16 (p = 0.03), for partial HBeAg-responders the level decreased from 126.5 
pg/ml at week 0 to 4 pg/ml at week 16 {p < 0.001) and for HBeAg-nonresponders 
from 130 pg/ml at week 0 to 73 pg/ml at week 16 {p = 0.001} {fig 2b). Within the 
group of HBeAg-nonresponders, only 5 patients did not show a decrease in HBV DNA 
level during therapy. The pretreatment HBV DNA level found for HBeAg-responders was 
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fig 1. A decrease in the median HBeAg level resulted in a statistically significant reduction of the 
HBeAg level at 12 and 1 6 weeks of treatment. A statistically significant decrease in median the 
HBV DNA level occurred at 8 and 16 weeks of treatment (see results, quantitative HBeAg and 
H BV DNA analysis). 
significantly tower than that for partial HBeAg-responders and HBeAg-nonresponders (p 
= 0.05). 
Paired observations of serum HBV DNA 4 weeks prior to the start of treatment and at 
the start of treatment for 36 patients showed a spontaneous decrease in HBV DNA 
level of 50 % or more in 10 patients (28%, 95% Cl 14-45). Such a decrease was 
observed during treatment, i.e. between HBV DNA levels at the start of treatment and 
after 16 weeks of treatment, in 30 out of 39 patients (77%, 95% Cl 61-89). Because a 
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fig 2. Median HBeAg p/n ratio for HBeAg-responders ( ---·), partial HBeAg-responders 
1·---•) and HBeAg-nonresponders ( +---+ l reveals a decrease for the first 2 groups with 
a persistent low HBeAg level for HBeAg-responders and a rebound to pretreatment levels for 
partial HBeAg- responders. The median level of HBV DNA in HBeAg-responders, partial HBeAg-
responders and HBeAg-nonresponders is shown. A rebound to pretreatment levels is observed 
for partial HBeAg-responders and HBeAg-nonresponders. There is a statistically significant 
difference in pretreatment levels between HBeAg-responders and partial and nonresponders (see 
text, results) 
decrease in HBV DNA level of 50% or more occurred significantly more often during 
treatment than spontaneously (28%). this event was related to therapy in approximately 
70% of patients. We therefore evaluated this response to therapy in the subgroups of 
HBeAg-responders, partial responders and nonresponders (table 2)_ Two patients from 
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the HBeAg-nonresponder group did not show a marked decrease in serum HBV DNA 
level. Since a!l other patients showed a decrease in either serum HBeAg !eve! or serum 
HBV DNA leve[, only 11 % were true nonresponders in this study. 
tab!e 2: Cumulative number of patients with a 50% HBV DNA decrease 
HBeAg-resp HBeAg-partial resp HBeAg-nonresp 
n= 11 n=13 n=20 
week 0 4/9 4/10 4/17 
week 16 10/10 11 !12 15/18 
week 32 10/10 11/12 16/18 
week 52 10!1 0 11/12 16/18 
DISCUSSION 
During lFN treatment 3 major decisions have to be made: 1 - stop therapy because of 
success, 2 - continue therapy because of partial response, 3 - stop therapy because of 
failure. Decision 1 can be based on information about HBeAg status. In the present 
study HBeAg negativity on 2 successive occassions appeared to be a stable endpoint of 
therapy. Decision 2 can be based on the presence or absence of a declining HBeAg 
level. The decrease in HBeAg and subsequent rebound to pretreatment levels after 
cessation of therapy in a!l partial HBeAg-responders together indicate that spontaneous 
HBe-seroconversion is unlikely to occur and that only prolongation of therapy may result 
in HBe-seroconversion (5). If no decrease in serum HBeAg leve! can be found, additional 
HBV DNA measurement is required. When the HBV DNA level has decreased, further 
therapy is indicated. Decision 3 requires absence of a response of the HBeAg or HBV 
DNA level after a period of 16 weeks of IFN treatment. Of course, it may be necessary 
to stop therapy because of unacceptable side effects. 
The HBeAg assay described in this study requires serial dilutions of patient serum and 
the quantity of HBeAg cannot be expressed in weight units/volume unit. Because of the 
clinical relevance of the monitoring of HBeAg levels, as described above, development 
of a standard quantitative HBeAg assay is highly desirable. 
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We conclude that a quantitative HBeAg assay can be used for both monitoring and 
endpoint determination of antiviral therapy. The value of HSV DNA testing is that it 
identifies a response to treatment in patients with high initial levels of replication 
activity who do not exhibit a marked decrease in serum HBeAg level. 
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CHAPTER 4 
MODULATION OF ALPHA-INTERFERON EFFECTS BY INDOMETHACIN AND 
PARACETAMOLIN CHRONIC HEPATITIS B. 
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The contents of this chapter have been submitted for publication to the Journal of 
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SUMMARY 
Indomethacin and paracetamol can prevent influenza-like symptoms. We investigated 
whether antiviral effects of alpha-interferon in patients with chronic hepatitis 8 
(suppression of active viral replication as well as enhanced expression of HLA class I 
antigens) occur during indomethacin and paracetamol administration. 
Patients with chronic HBeAg positive hepatitis received for 2 weeks either: leukocyte 
alpha-interferon intramuscularly {group I, n = 8), !ymphoblastoid alpha-interferon 
subcutaneously (group II, n = 1 Q), acyclovir intravenously (group til, n = 11} or a 
combination of lymphoblastoid alpha interferon and acyclovir (group IV, n=5). In 
addition group I received paracetamol (500 mg 4 times daily) and groups II and IV 
indomethacin retard (75 mg 2 times daily) during the first 3 days of antiviral therapy. 
Indomethacin and paracetamol successfully prevented influenza-like symptoms. The 
drop in DNA polymerase activity after initiation of treatment was comparable in groups 
I, II and IV. Beta 2 microglobulin concentration, a measure of HLA class I antigen 
turnover, rose to a similar degree in groups t, II and IV; no rise was found for group HI. 
A statistically significant decrease in DNA polymerase activity and increase in beta 2 
microglobulin level was noticed in groups I and !1. 
Administration of alpha-interferon results in a decrease in markers of viral replication 
and enhanced expression of HLA antigens, despite indomethacin and paracetamol 
administration. Since indomethacin and paracetamol prevented the influenza-like symp-
toms of alpha-interferon treatment, these drugs can be given to avoid these symptoms. 
Keywords: chronic hepatitis B, a-interferon, side effects, indomethacin, paracetamol. 
48 
INTRODUCTION 
Therapy with alpha ·Interferon (a~JFN} evokes influenza·like symptoms at initiation of 
treatment. The first week of treatment is characterized by fever, sometimes as high as 
40 °C, with headache, myalgia, arthralgia and general malaise. Reduction of the dose of 
alFN will decrease these side effects, but they tend to diminish of their own accord 
within two or three weeks of the start of therapy. However, the severity of these 
symptoms may cause interruption of professional activities and even hospitalization 
during the initial phase of therapy. Therefore the administration of analgesics to prevent 
influenza-like symptoms would seem to be justifiable. It is, however, not known 
whether analgesics interfere with the antiviral effect of a-IFN. Since the antiviral state 
of the cells, as induced by IFN, is reported to be related to continuous activity of cyclo-
oxygenase to catalyze the first step of prostaglandin biosynthesis {1), inhibition by 
analgesics may have a negative influence on the effects of a-IFN treatment. On the 
other hand prostaglandins of the E series have been reported to inhibit induction of 
natural killer cell activity and killer cell activity by IFN {2). Arachidonic acid metabolites 
clearly have a dual effect on the antiviral activity induced by a-JFN. We therefore 
investigated the effects of indomethacin and paracetamol administration during a-IFN 
treatment for patients with a chronic active hepatitis 8 infection. 
METHODS AND MATERIALS 
Patients and treatment. 
All patients had chronic HBeAg positive hepatitis and no history or signs of recent 
alcohol abuse, drug addiction or posttransfusion hepatitis. Leukocyte alpha interferon {a-
lFN-Ie) was supplied by Cantell (3), lymphob!astoid alpha interferon (a-lFN-Iy) and 
acyclovir {ACV) by Wellcome, Beckenham, United Kingdom. Four different therapies 
were given for 2 weeks: group I {n=Sl received a-IFN-Ie {12 MU daily) intramuscularly, 
group II (n = 1 0) received a-IFN-ly {5 MU daily) subcutaneously, group Ill {n = 11) 
received ACV {30 mg/kg daily) intravenously and group IV {n=5) received a combinati-
on of the treatments of groups It and Ill. During ACV administration a urinary output of 
2000 ml daily was maintained to preserve normal renal function. In addition group I 
received paracetamol (4 x 500 mg daily) and groups II and IV indomethacin retard (2 x 
75 mg daily) during the first 3 days of therapy. 
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Serologic tests. 
All serum samples taken before (week 0), during (week 1 l and after treatment (week 2) 
were assayed for beta 2 microglobulin (82M) by RIA (Pharmacia Diagnostics AB, 
Uppsala, Sweden). aspartate aminotransferase (AST) and creatinine using an automated 
system (SMA 12), HBeAg by RIA (Abbott laboratories, !11., USA) and hepatitis B virus 
DNA polymerase activity {DNAp) by standard methodology: 800 pi of serum were 
centrifuged for 4 hours at 30,000 rpm and 4 °C in a SW41 rotor. The virus pellet was 
resuspended in 40 .ul PBS and added to 1 05 pi of the following reaction mixture : 160 
mM Tris-HCI, pH 7.5, 40 mM MgCJ2, 120 mM NH4CI, 50 pM dATP, 50 pM dGTP, 50 
pM dCTP, 0.3 pM 3HdTTP (50 CUmmol), 1.0 % Nonidet P40, 0.3 % 2-Mercaptoetha-
nol, 33 % bid est, 9 % PBS. Incubation for 3 h at 37 °C was foHowed by spotting 100 
,ul on a Whatmann 3M chromatography paper which was air-dried for 30 min. DNA was 
fixed on the filter by overnight incubation in trichloroacetic acid (TCA) (5 % w/v), which 
also eluted the excess radioactive !abet and then dried at 80 °C for 1 h. Subsequently 
the incorporation of 3HdTTP was assayed by measuring the counts per minute (cpm) of 
the filters in insta-gel (United Technologies Packard) in a PW4540 liquid scintilation 
analyzer. In each test run 2 positive control samples and 5 negative control samples 
were included and assayed as described above. The test cut-off was the mean of the 
negative samples plus 3 standard deviations. 
Statistics. 
Data were compared by the Wilcoxon signed-rank test using an Olivetti M240 personal 
computer and STAT A {Computing Resource Center, Los Angeles, USA). 
RESULTS 
Both indomethacin and paracetamol prevented or diminished influenza-like symptoms 
when administered during the first 3 days of a-IFN treatment. Body temperature 
remained normal to subfebrile in most patients (fig 1 ). Some patients experienced mild 
influenza-like symptoms, such as headache, fatigue, myalgia and general malaise, but 
continuation of normal daily routine remained possible. Hospitalization was only required 
for intravenous administration of ACV. 
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Figure 1. Body temperature during the first week of a-JFN treatment of a patient who did not 
receive paracetamol or indomethacin {a), median body temperature of 3 patients receiving 
paracetamor (500 mg 4 times daily) (b) and in 3 patients receiving indomethacin (75 mg 2 times 
daily) (c) during the first 3 days of a-IFN therapy. 
Virus replication. 
Inhibition of viral replication, as measured by DNAp activity, occurred in all groups after 
1 and 2 weeks. The median percentage of activity after 1 and 2 weeks compared to the 
pretreatment level was 44 and 47 % for group I (p < 0.05), 32 and 20 % for group II 
(p < 0.051, 45 and 59 % for group Ill and 17 and 15 % for group IV (fig 2), 
respectively. No decrease in the serum HBeAg titer was observed except for a non-
significant drop in group IV at 2 weeks. 
Beta 2 microglobulin levels. 
Serum B2M levels were tested to assess HLA class I antigen turnover during a-IFN 
therapy. Only 3 patients showed slightly elevated pretreatment levels of B2M; 1 patient 
in group II (3.7 mg/1), 1 patient in group Ill (3.6 mgfl) and 1 patient in group IV (4.6 
mg/1, normal level < 3.0 mg/1). B2M levels in groups I, II and IV exhibited a rise after 
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Figure 2. Percentage of HBV DNAp activity before (week 0), during (week 1) and after 
treatment (week 21 in groups I, II, Ill and IV. Statistically significant decreases were found at 
week 1 and 2 for groups 1 and 11. A significant decrease was not reached in group IV because of 
the small number of patients. 
the start of treatment. No increase was found for group 1!1 (fig 3). One and 2 weeks 
after initiation of treatment, the median percentual increments in serum level were: 65 
and 74% for group l {p < 0.05), 61 and 59 % for group 11 (p < 0.05L 20 and 17 % 
for group Ill and 58 and 54 % for group IV, respectively. 
Hepatitis activity. 
Serum AST levels were assessed to determine the change in hepatocellular lysis as a 
possible cause of the increment in B2M. Compared to baseline levels, no significant 
increase was found for any of the treatment groups. The median percentages of the 
AST level at weeks 1 and 2 compared to week 0 were: 98 and 90 % in group 1, 110 
and 113 % in group 11, 105 and 122 % in group l1l and 106 and 98 % in group IV, 
respectively. 
Serum creatinine levels remained stable in all groups. 
52 
% B2M 
200 
0 ' 2 
WEEK 
group I 
0 ' 2 WEEK 
group II 
0 ' 2 WEEK 
group Ill 
0 ' 2 WEEK 
group IV 
Figure 3. Percentual increments in 82M level before (week OL during (week 1) and after 
treatment (week 2) in groups I, !1, lll and IV. Statistically significant increments were found for 
groups I and II. 
DISCUSSION 
The antiviral effect of a-IFN consists of depression of viral particle synthesis and cellular 
membrane changes with enhanced expression of HLA class I antigens (4,5). Depression 
of viral particle synthesis is reflected by the serum HBV DNAp activity, which is 
associated with virus particles in serum and responds to antiviral treatment within days 
(6}. We therefore used serum HBV DNAp activity to demonstrate the antiviral effect of 
a--IFN. As an indirect parameter of HLA class I antigen expression, B2M serum levels 
were tested. Increase in HLA class ! antigen turnover is associated with an increase in 
serum B2M concentration. If renal function and cytolysis remain stable, an increase in 
serum 82M concentration must be due to an increase in HLA class I antigen expression 
on cellular membranes. The stable levels of serum AST excluded an increase in 
hepatocellular necrosis and stable serum creatinine levels indicated that the renal 
clearance of 82M did not change. A statistically significant decrease in serum DNAp 
activity and increase in serum 82M level were found for patients of group I, indicating 
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that despite paracetamol administration inhibition of viral particle synthesis and 
increased HLA class I antigen expression occurred during a-!FN therapy. The same 
results were found for group II which received indomethacin during the first 3 days of a-
lFN administration. Patients in group Ill showed no increase in 82M level, as was 
expected because ACV does not increase HLA ctass I antigen expression. The decrease 
in DNAp activity and increase in B2M level during combination a-IFN and ACV therapy 
was at least as evident in group lV as in groups I and II, despite indomethacin 
administration during the first 3 days of treatment. We conclude that indomethacin and 
paracetamol can prevent the influenza-like symptoms of a-IFN treatment, when 
administered during the first 3 days of treatment. Furthermore, since a significant effect 
of a-lFN on viral replication activity and HLA class ! antigen turnover could still be 
demonstrated, these drugs can be used to prevent the influenza-like side effects of a-
IFN treatment. 
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CHAPTER 5 
ZIDOVUDINE INHIBITS HEPATITIS S VIRUS REPLICATION 
The contents of this chapter have been submitted for publication to Antiviral Research 
under the same title with the following authors: Luuk Berk, Solko W Schalm and Rudolf 
A Heijtink. 
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SUMMARY 
Hepatitis 8 virus DNA polymerase is a viral enzyme that can use viral DNA as wet! as 
viral RNA as a template for DNA synthesis. Since both activities are essential for the 
production of new virus particles, blockage of this enzyme should reduce viral replica-
tion activity. 
In the present study the in vitro effect of zidovudine triphosphate on hepatitis B virus 
DNA polymerase activity and the in vivo effect of zidovudine on viral replication activity 
in chronic HBsAg-positive patients are investigated. Zidovudine triphosphate inhibited in 
vitro DNA polymerase activity by fifty percent at a concentration of 0.3 pM. Serum 
DNA polymerase activity was significantly reduced in seven patients who received 
zidovudine (200 mg oraHy four times daily) for one week. A dose response effect was 
suggested by the results found for six patients who received 100 mg, 200 mg and 300 
mg orally four times daily for one week with 2 drug-free weeks between each course. 
We conclude that zidovudine may be of value for nonresponders to alpha-interferon 
therapy or patients with high initial levels of viral replication prior to the start of 
interferon treatment. 
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INTRODUCTION 
The hepatitis B virus (HBV) has an endogenous DNA polymerase <DNAp) activity that 
can be detected in the serum of patients with active virus replication (1 ). This DNAp 
induces synthesis of viral DNA by DNA-dependent DNAp activity and RNA-dependent 
DNAp activity (2). Both activities are essential for HBV replication. lnhibition of these 
steps of the replication cycle therefore should reduce the formation of new virus 
particles. 
Alpha interferon (a-IFN) can be considered the cornerstone of antiviral therapy for 
chronic hepatitis B. Treatment for 12 -16 weeks with 5 MU daily or 10 MU every other 
day results in the induction of virus latency {HBe-seroconversion} in approximately 25 
% of patients (3). Response to a-IFN treatment is related to the initial level of viral 
replication, with poor results for patients with high levels of replication activity (4}. To 
increase the response rate for a-JFN, it therefore appears rational to add to the 
treatment regimen an antiviral agent with a different target in the multiplication cycle 
than those influenced by a-IFN. Administration of nucleoside analogues in combination 
with a-JFN to patients who do not respond to monotherapy or have high initial 
replication levels prior to the start of treatment may thus increase the response to 
treatment. Several nucleoside analogues have already been included in the treatment of 
chronic hepatitis 8: acyclovir with poor success (5) and adenine-arabinoside (-monop-
hosphate) with moderate success but severe toxicity (6). 
Zidovudine (3'-azido-3'-deoxythymidine, AZT) is widely used to inhibit in vivo human 
immunodeficiency virus (HJVJ replication since it has been demonstrated that AZT leads 
to a significant improvement in the survival of AIDS patients (7). Zidovudine 
triphosphate (AZT TP) has also been reported to inhibit HBV DNAp activity in vitro (8). 
In order to confirm these findings, we investigated the in vitro effect of AZT TP on HBV 
DNAp activity and the in vivo effects of zidovudine on hepatitis 8 virus replication 
activity. 
METHODS AND MATERIALS 
Virus isolation. 
Hepatitis B virus (HBVl was isolated from HBV DNA positive serum by ultracentrifuga-
tion in a SW41 rotor for 3 hat 30,000 rpm and 4 °C. The pellet was resuspended in 
phosphate buffered saline (PBS), layered on a discontinuous gradient of 10 to 20 % 
sucrose in sodium, tris HCI and EDTA {NTE) buffer, pH 7.5, and centrifuged overnight in 
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a SW27 rotor at 25,000 rpm and 4 °C. The pellet was resuspended in PBS and 
immediately assayed for DNAp activity. 
HBV marker assays. 
ONAp activity measurements were performed in duplo as described by Howard using a 
modification of the elution of unincorporated tritiated thymidine-methyl-5'-triphosphate 
(3HdTTP) as described by Fang et al (9, 1 0). Forty pi of virus suspension were added to 
105 pl of the following reaction mixture : 1 60 mM Tris-HCI, pH 7 .5, 40 mM MgCI2, 
120 mM NH4CI. 50 pM dATP, 50 pM dGTP, 50 pM dCTP, 0.3 pM 3HdTTP (50 
Ci/mmol, Amersham, UK), 1.0 % Nonidet P40, 0.3 % 2-Mercaptoethanol, 33 % bidest, 
9 % PBS. Incubation for 3 h at 37 °C was followed by spotting 100 p! on Whatmann 
3M chromatography paper which was air-dried for 30 min. DNA was fixed on the filter 
by overnight incubation in trichloroacetic acid (TCA) {5 % w/v) which also eluted the 
excess 3HdTTP, and then dried at 80 °C for 1 h. Incorporation of 3HdTTP was assayed 
by placing the filters in 10 ml scintillation counting fluid ([nsta-gel, Packard, 111.) in a 
PW4540 liquid scintillation analyzer. 
To assay HBV DNAp activity in patient serum 800 ,ul samples were diluted to 11 ml in 
PBS and centrifuged for 4 hours at 30,000 rpm and 4 °C in a SW41 rotor. The virus 
pellet was resusp~nded in 40 ,ul PBS and added to 1 05 ,u! assay mix, as described 
above. Five negative control samples and 2 positive control samples were included in 
each test run. Samples were considered positive when the cpm exceeded the mean 
cpm of the negative control samples plus 3 standard deviations {approximately 150 
cpm). HBV DNA was measured by liquid phase hybridization {Genostics, Abbott, Ill., 
U.S.A.); results exceeding 5 pg/ml were considered positive. Serum HBsAg and HBeAg 
were tested by RIA (Abbott, Ill., U.S.A.) 
HBV DNAp inhibitors. 
A sodium salt of 3'azido 2'3'dideoxythymidine triphosphate (AZT TP) was donated by 
Prof. E. de Clercq, Rega Institute, Leuven. A stock solution of 200 ,uM AZT TP in bidest 
was kept at -20 °C. The concentration of AZT TP in bidest was assessed by high 
pressure liquid chromatography {dr. J. Balzarini, Rega Institute, leuven). A sodium salt 
of phosphonophormate {foscarnet, PFA) was provided by Dr. M. Kuipers, Astra, the 
Hague. A stock so! uti on was made of 10 mM in bidest and stored at 4 °C. 
Patients. 
AH patients (n=7) had had HBsAg positive hepatitis for more than 1 year, with stable 
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levels of HBeAg, DNAp activity and HBV DNA in serum as well as HBcAg in the liver. 
None of the patients had antiHDV antibodies in serum or HDAg in the liver. Two had 
cirrhosis and 3 were antiHIV positive with normal OKT4 positive cell counts. 
Treatment. 
Zidovudine was given in 100 mg capsules, orally. Seven patients (Group I) received 4 x 
200 mg zidovudine daily for 1 week. Six patients (group ll} then received increasing 
doses of the drug: 4 x 100 mg, 4 x 200 mg and 4 x 300 mg zidovudine daily for 1 
week with 2 drug-free weeks between each course. 
Statistics. 
Pre- and posttreatment results were compared by the Wilcoxon sign test. 
RESULTS 
ln vitro results. 
Characteristics of the virus suspension, obtained from the serum of a patient with 
chronic hepatitis B, are given in table 1. Inhibition of 3HdTTP incorporation by foscarnet 
(PFA) was used to identify HBV DNA-specific DNAp activity and inhibition by actinomy-
cin D {act-D) to identify the proportion of activity due to DNA-dependent DNAp activity 
and RNA-dependent DNAp activity (11 ). A final concentration of 10 pM PFA in the 
assay mixture resulted in an inhibition of HBV DNAp-specific activity of 91 %. Addition 
of act-O in a final concentration of 1 00 pM resulted in an inhibition of (DNA dependent-) 
DNAp activity of 83 %. Inhibition by AZT TP is presented in figure 1. A 50 % inhibition 
can be estimated for an AZT TP concentration of 0.3 pM in the test. Results were 
reproducible for sera obtained from different patients and in different sets of tests. 
In vivo results. 
DNAp activity decreased in all patients of group I after 4 days of treatment and were 
still low on day 7 {fig 2). Median DNAp activity diminished from 3036 cpm on day 0 to 
819 cpm on day 4 (median percentual decrease compared to baselines values: 50%, 
95% Cl 14-73%) and 999 cpm on day 7 (29%, 95% Cl 12-72%, p=0.008). In group ll 
a dose-response effect was observed; median DNAp activity on days 4 and 7 was 85% 
(95% Cl 54-188%) and 76% (95% cr 57-115%), respectively, of initial activity during 
4 x 100 mg, 57% (95% Cl 19-107%) and 65% (95% CJ 31-108) during 4 x 200 mg 
and 40% (95% Cl 25-67%) and 54% (95% Cl 6.6-136) during 4 x 300 mg zidovudine 
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Table 1: Characteristics of HBV suspension for in vitro assay 
DNAp activity (cpm} 
40 pi sample 1070 
negative control sample 46 
40 pi sample + PFA 1 0 pM 102 
40 pi sample + act D 1 00 pg/ml 173 
background radiation 22 
The serum, obtained from a male donor who had a chronic HBeAg, HBV DNA positive hepatitis 
acquired during his work as an ambulance nurse, was concentrated 20-fold after sedimentation 
and resuspension in PBS as described under Methods and Materials. No clinical or serological 
indications of other viral infections were found. The patient was antiHDV, antiHIV, lgM antiHAV, 
!gM anti EBV and lgM antiCMV negative. The negative control sample contained 40 pi of 
pelleted serum from a healthy human donor. PFA = foscamet, act D = actinomycin D. 
% HBV DNAp 
'ocr----~ 
so 
so 
40 
20 
oL------L----~~-----L------~----~ 
0 0.01 0.1 1 10 100 
"M AZT TP 
Figure 1. Percentage DNAp activity of a human HBV serum preparation during different concen-
trations of AZT TP. 
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HBV DNAp 
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Figure 2. Percentage residual HBV DNAp activity in serum during treatment with zidovudine 
(200 mg orally 4 times daily). 
daily (fig 3). No statistical significance was observed because 1 out of 6 patients did 
not respond to therapy. HBV DNA also tended to decline but no statistical significance 
could be found because 1 patient did not respond. During 4 x 300 mg zidovudine the 
median HSV DNA level decreased from 227 pg/ml on day 0 to 196 pg/ml on day 4 
{median percentage compared to baseline values: 105%, 95% Cl 62-1 09%) and 161 
pg/ml on day 7 (77%, 95% Cl 41-124%). 
DISCUSSION 
The results of our in vitro study confirm those reported by Nordenfelt et al. Since the 
concentration of AZT TP that yields 50 % inhibition is comparable to the concentration 
of the label used in this assay, the drug has an affinity for viral DNAp similar to that of 
the natural substrate thymidine TP. In vitro AZT TP appears to be a moderately 
effective inhibitor of DNA dependent HBV DNAp activity. 
The results show that a statistically significant suppression of HBV DNAp activity is 
achieved in chronically infected patients by the administration of zidovudine 4 times 
daily. The repeated 1-week courses with increasing doses ranging from 400 to 1200 
% HBV DNAp 
200 
0 4 7 
day 
AZT 400 mg 
0 4 7 
day 
AZT 800 mg 
0 4 7 
day 
AZT 1200 mg 
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Figure 3. HBV DNAp activity expressed as a percentage of residual activity during increasing 
doses of zidovudine, suggesting a dose-response effect. 
mg daily, provides an estimation of the dose versus response effect. 
These findings are not in accordance with data of other investigators who found no 
effect of zidovudine on HBV replication in patients with concurrent HBV and HIV 
infections (12, 13, 14). Such patients usually have high levels of HBV replication activity. 
A lack of effect of zidovudine on HBV replication in symptomatic HlV-infected patients 
may be explained by the use of the insensitive semiquantitative dot-blot method for 
HBV DNA measurement (15). 
In vitro experiments with HBV-producing cell lines and AZT showed inhibition by 
noncytotoxic doses of the drug, indicating that sufficient phosphorylation of AZT occurs 
in these models (16, 17, 18). We found the most pronounced inhibition of HBV DNAp on 
day 4 during each course with no further decline and sometimes even an increase in 
some patients. An escape mechanism of the virus might explain the lack of further 
effect on replication activity. Our results for immunologically competent patients should 
be confirmed by a randomized placebo-controlled study to evaluate the effect of 
zidovudine as a single agent on HBV replication activity. lf this study confirms the 
antiviral effect of zidovudine in chronic hepatitis B, a randomized placebo-controlled 
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study to investigate the effect of zidovudine in combination with a-IFN in patients who 
do not respond to monotherapy with a-JFN is indicated. 
The present results suggest that zidovudine may be effective in lowering viral replication 
activity in immunocompetent chronic HBV-infected patients. Since AZT can be given 
orally, further study is indicated to assess the clinical efficacy and risks of this drug. 
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CHAPTER 6 
BENEFICIAL EFFECTS OF PHYLLANTHUS AMARUS FOR CHRONIC HEPATITIS B, 
NOT CONFIRMEO 
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SUMMARY 
The positive results of Thyagarajan et al with P. amarus to eradicate HBsAg in chronic 
HBV infected patients, stimulated us to investigate the effects of this plant on HBsAg 
seroconversion in our own patient population. We designed a cross-over study for 10 
patients who were HBsAg positive for more than 1 year. All patients were antiHD and 
antiHIV negative. They were randomly assigned to receive double blind either P. amarus 
from Suriname 3 x 200 mg daily for 28 days followed by placebo (spinach) 3 x 200 mg 
daily for 28 days {group 1) or placebo followed by P. amarus {group 2). Clinical 
evaluation was done four-weekly to register side effects. Blood sampling was done 
weekly to monitor changes in HBsAg (RIA), HBeAg (R!A) or AST status. Follow-up was 
performed until 12 weeks after onset of therapy. 
No marked clinical changes were observed during treatment nor during follow-up. No 
changes in HBsAg, HBeAg or HBV DNA level nor in AST level were observed during 
treatment with P. amarus or placebo. No difference between HBV DNA positive patients 
(n=6) or HBV DNA negative patients (n=4) could be observed. 
We conclude that P. amarus from Suriname did not effect the clinical, biochemical or 
HBV virological status of our patient population. In view of our negative results and 
those of leelarasamee et al with P.amarus from Thailand, we think that the results of 
Thyagarajan et al need to be confirmed with P. amarus from India in a European centre 
to conclude that P. amarus might be an effective drug in the treatment of chronic 
hepatitis type B in European patients. 
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INTRODUCTION 
Phyllanthus amarus is a tropical plant that is used as a herbal medicine in southern India 
for over 2000 years against icteric and various other diseases. Several antihepatotoxic 
and potential antiviral substances have been isolated from P. amarus (1 ,2,3}. In 1982 in 
vitro inhibition of H8sAg-antiHBs binding was reported by aqueous extracts of P. 
amarus (4). Further evaluation of this herb in the woodchuck (Marmota MonaxJ model 
infected with woodchuck hepatitis virus showed in vitro inhibition of WHsAg-antiWHs 
binding and WHV DNA polymerase activity. In vivo studies showed decrease of serum 
WHsAg titers and inhibition of WHV DNA polymerase activity {5). In 1988 a placebo 
controlled study reported a high incidence of HBsAg eradication in chronic HBV infected 
patients treated with a dried plant preparation (6). These positive results stimulated us 
to investigate the effects of this plant on HBsAg seroconversion in our own patient 
population. 
METHODS 
Patients. 
Ten patients who had been HBsAg positive for more than 1 year were entered in the 
study. All patients were antiHD and antiH!V negative. Patient characteristics are given 
in the table. 
Treatment and design. 
Patients were randomly assigned to one of two groups to receive double blind either P. 
amarus 3 x 200 mg daily for 28 days followed by placebo 3 x 200 mg daily for 28 days 
{group 1) or placebo followed by P. amarus (group 2). Clinical evaluation was done four-
weekly to register side effects. Blood sampling was done weekly and follow-up was 
performed until 1 2 weeks after onset of therapy. 
Medication. 
P. amarus plants were gathered in Suriname and kept fresh frozen. After freeze-drying 
and grinding preparations were sterilized by gamma-radiation, and dispersed in 1 00 mg 
capsules. For placebo {spinach) the same procedure was performed. 
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laboratory assessments. 
Serum HBsAg and HBeAg were assessed by RIA (Abbott, IH.). Serum HBV DNA was 
measured by liquid phase hybridisation (Abbott, 111.) and serum aspartate aminotransfe-
rase (ASTl by using an automated system (SMA 12). 
Statistics. 
Cross-over analysis was performed for HBsAg p/n ratio to assess treatment effect, 
period effect or a combined treatment x period effect (7). 
RESULTS 
No marked clinical changes were observed during treatment nor during follow-up. Tabel 
1 shows the results of P. amarus on HBsAg and HBeAg level and on HBV DNA level in 
individual patients. No changes in HBsAg, HBeAg or HBV DNA level nor in AST level 
were observed during treatment with P. amarus. No difference between HBV DNA 
positive patients (n=6l or HBV DNA negative patients {n=4) could be observed. Table 
2 presents the cross-over analysis of HBsAg levels during P. amarus and placebo 
treatment. 
DISCUSSION 
The cornerstone of therapy for chronic hepatitis 8 is alpha interferon (IFNJ that induces 
virus latency in a significantly greater proportion of patients than spontaneously occurs 
in control patients ($). However, a considerable amount of patients does not benefit 
from a standard lFN treatment of 1 2 to 16 weeks. Addition of an antiviral agent with a 
different target in the viral replication cycle than the enhanced cytotoxic immunity 
induced by IFN would therefore be likely to improve the treatment response. The in vitro 
and in vivo results of P. amarus from India on HBsAg-antiHBs binding and HBs-
seroconversion {4,6) suggested that P. amarus could be of value to improve lFN 
treatment results. 
We did not find a beneficial effect of P. amarus from Suriname on the virological status 
of our patients, nor on the clinical or biochemical status. The quality of the herbs used 
in our study was guaranteed by preparation according to routine procedures in a 
pharmacological laboratory {Prof R.P. Labadie, department of Pharmacology, University 
of Utrecht). Leelarasamee et ai found no effect of P. amarus from Thailand either {2). P. 
amarus is a common herb found in several tropical regions world-wide. In view of the 
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table 1. 
EFFECT QF P. AMARU:;! QN HBsAg AND HBei>g TITER§ AND SER!,!M A:;!T LEVEL 
before therapy end of therapy 
pat sex age HBsAg HBeAg HBV DNA HBsAg HBeAg HBVDNA 
{pin)" {p/nJ" {pg/mll .. p/nJ" {p/nJ" {pg/miJ"" 
m 28 60.6 8.2 98 63.2 4.3 73 
2 m 36 37.7 9.5 32 50.1 7.1 12 
3 m 36 199.4 10.5 76 31.7 9.4 48 
4 j 26 79.7 10.8 < 1.6 86.9 10.4 4.4 
5 m 40 41.8 8.6 6.2 59.7 9.7 3 
6 j 52 71.1 7.9 13 63.4 6.5 7.7 
7 m 24 40.1 4.0 <1.6 41.8 2.5 <1.6 
8 m 30 76.4 8.1 27 84.8 12.8 25 
9 m 35 55.8 0.9 < 1.6 64.5 0.7 <1.6 
10 m 59 55.4 0.8 <1.6 44.5 0.8 < 1.6 
• HBsAg and HBeAg were tested in a fixed dilution of serum throughout the study and 
expressed as a ratio of cpm in patient serum (p) and in negative control serum (n). 
•• AST normal < 30 U/1 
results of Thyagarajan et al {4,6) and the support of these data by in vitro and in vivo 
results in the woodchuck model, there may be a difference in fenotype of these plants 
depending on the region of origin. We think that the data of Thyagarajan et ar need to 
be confirmed with P. amarus from India in a European centre to conclude that P. amarus 
might be an effective drug in the treatment of chronic hepatitis type 8 in European 
patients. 
table 2. 
period 
group 1 
treatment 
HBsAg p/n ratio 
group 2 
treatment 
HBsAg p/n ratio 
p 
CROSS-OVER ANALYSIS OF HBsAg 
PA 
mean+ SD 
58.8 + 27.7 
plac 
63.7 + 16 
0.26 
2 
plac difference sum 
mean+ SD mean + SO mean + SO 
56.6 + 18.3 2.2 + 11.1 
PA 
61.5 + 19 2.1 + 7.1 
0.31 d1 = d2: 0.01 
d1 =-d2: 0.52 
115.4 + 45.6 
125.2 + 34.4 
0.29 
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PA = Phyllanthus amarus; plac = placebo; difference = (HBsAg p/n ratio) period 1 - (HBsAg 
p/n ratio) period 2, d1 = difference group 1, d2 = difference group 2; summ = (HBsAg p/n 
ratio) period 1 + (HBsAg) period 2; p = p value obtained by t-test for unequal means. Equality 
of d1 and d2 indicates that no treatment effect was found. The sum of d1 and d2 excluding 0 
indicates that no period effect was found. Equality of the sum of period 1 and period 2 for group 
1 and 2 indicates that no treatment x period effect was found. 
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CHAPTER 7 
ALPHA L YMPHOBLASTOID INTERFERON AND ACYCLOVIR FOR CHRONIC HEPATITIS 
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SUMMARY 
Ten patients with chronic hepatitis type D were treated during 4 months with alpha 
!ymphob!astoid interferon in combination with two 2-week courses of acyclovir. Median 
percentage of HDAg-positive hepatocytes decreased from 11 to 1, p :;;: 0.0225. 
Patients with no liver HDAg expression after treatment (n = 5) showed improved AST 
levels (normal in 4) and diminished liver cell inflammation. One patient, who cleared 
HDAg has complete biochemical remission of his liver disease with 2 years of follow-
up. Five patients with persistent, albeit low, HDAg expression in the liver, had continu-
ed liver cell destruction (AST elevated and/or abnormal biopsy). No evidence for an 
enhancing effect of acyclovir for interferon therapy was observed. 
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INTRODUCTION 
Hepatitis Delta virus (HDV) complicating a hepatitis 8 virus (HBV) infection, although 
uncommon in North-Western Europe, is a serious disease. Cirrhosis is often found in 
patients between 30 and 40 years of age (1 ). Results of treatment with corticosteroids 
or interferon OFN) have been inconclusive. Suppression of serum HDV RNA by JFN is 
frequently observed but sustained inactivation of the liver disease is seldom obtained 
(2,3,4). During the last few years, several aspects of the replication cycle of HDV and 
the role of delta antigen (HDAg) for genome replication have been elucidated (5 ,6). No 
viral enzyme activity has been recognized as a potential target for antiviral therapy. 
Furthermore, it now appears that HDV is not in itself cytopathic but livercell necrosis 
usually occurs in condition of replication of both HDV and HBV. A rational goal of 
therapy is to interfere with HDAg synthesis and to suppress HBV replication. A!pha-IFN 
is considered an antiviral agent acting through interference with viral messenger RNA 
and the most efficacious drug available for suppressing HBV replication. In 1985, when 
this study was designed, combination therapy of alpha lymphblastoid JFN and acyclovir 
(ACV) was thought to be the most promising therapy for chronic HBV infection (7). In 
this study we evaluated this combination therapy in patients with chronic hepatitis D. 
METHODS 
Patients. 
Ten patients from 2 hospitals (Hopital Laennec, Paris and University Hospital Dijkzigt, 
Rotterdam), with chronic HDV infection were entered in this study between december 
1985 and june 1988. All patients were male and antiHIV negative. Patient characteris-
tics are listed in table 1. 
Therapy. 
Alpha lymphoblastoid IFN (Wellferon, Wellcome, Beckenham, U.K.) 5 mega-unit daily 
was administered by subcutaneous injection during 4 months. Two 2-week courses of 
ACV 2 g daily intravenously were given during week 1 and 2 and week 8 and 9 of IFN 
administration. Slow release indomethacin 2 x 75 mg daily, or paracetamol 4 x 500 mg 
orally was given during the first 3 days of IFN administration to reduce side-effects. 
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Approval for the study was obtained from the human study commitees of both 
participating hospitals. 
table 1: patient characteristics at entry 
patient ••• trans~ known duration AST histology hepatocytes HBeAg HBV DNA antiHcv· (nr} (y) mission antiHO pes (mol (xULN) {%)pes for > 5 pg/ml 
HOAg HBcAg 
48 stay in 4 2.4 mild CAH 18 0 + 
endemic area cirrhosis 
2 24 i.v. drug- 21 2.4 mild CAH 5 0 ++ 
abuse cirrhosis 
3 50 stay in 24 1.4 mod CAH 0 + 
endemic area cirrhosis 
4 31 i.v. drug 96 2.4 sov CAH 0 0 
abuse cirrhosis 
5 26 i.v. drug 5 2.4 mod CAH 18 0 
ebuso mild fibr 
6 48 stay in 36 1.5 mod CAH 4 0 + 
endemic area cirrhosis 
7 27 homosexual 12 1.4 sov CAH 20 0 + 
contacts mild fibr 
8 29 i.v. drug 11 0.9 mod CAH 40 0 ++ 
abuse mild fibr 
9 36 unknown 18 4.6 mod CAH 0 0 
mild fibr 
10 27 i.v. drug 10 1.4 mod CAH 2 0 ++ 
abuse sev fibr 
+:absorbence> 0.473 (""detection limit), + +: absorbance of positive control 
CAH = chronic active hepatitis, fibr = fibrosis, mod = moderate, sov = severe 
Laboratory assessments. 
Pre-treatment sera were tested for HBsAg (R.I.A., AbbottL HBeAg (R.l.A., Abbott), 
HBV DNA (Genostics, Abbott) and antiHCV antibodies (E.l.A., Ortho). AntiHOV 
antibodies were tested by E.l.A. (Abbott). During treatment serum AST levels were 
assessed every 2 weeks in addition to assays for leucocytes, platelets and creatinin. 
Liver biopsies were taken before and within 10 weeks after treatment, and tested for 
HDAg by immunofluorescence and/or immunoperoxidase. Indirect immunofluorescence 
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was performed on paraffine slides. After deparaffination and pronase pretreatment, 
slides were incubated with human serum containing a high titer of !gG antiHDV 
antibodies, giving a specific staining for HDAg in a dilution of 1/30 in PBS and no 
staining for HBcAg and HBsAg. Paired pre- and post treatment biopsies were tested by 
this method. Fresh frozen tissue was tested by direct immunofluorescence and/or 
immunoperoxidase, using human serum derived antiHOV antibodies labeled with FITC 
or peroxidase. This serum gave a specific staining in a dilution of 1/80 in PBS for 
HDAg, while negative results were obtained for HBcAg and HBsAg. 
RESULTS 
0-16 weeks. 
Eight out of 1 0 patients were positive for liver HDAg before treatment. A marked 
decrease in liver HDAg expression was observed in post treatment biopsies. The 
median percentage of positive hepatocytes diminished from 11 to 1, p = 0.0225 
(Wilcoxon, signed-rank test). Three patients became negative for liver HDAg during 
treatment in addition to the 2 patients that were negative before treatment and 
remained negative in the post treatment biopsy (fig 1 ). 
The 4 patients with high HDV replication activity {HDAg in 1 5 - 40 % of hepatocytes) 
did not respond differently to treatment than the 6 patients with tow HDV replication 
activity (HDAg in 0- 5 %of hepatocytes). In the former group 2 patients became liver 
HDAg negative with normalization of serum AST and reduction in periportal infiltrate. In 
the latter group 1 patient became liver HDAg negative, 3 showed normalization of AST 
and 3 had a reduction in periportal infiltrate. 
Nine patients had elevated serum AST levels prior to treatment. Median AST level 
decreased from 2.0 to 1.0 x the upper limit of normal {ULN). Although this decrease 
was not statistically significant, AST normalized in 5 patients. Of 7 patients with a 
decrease of AST level during treatment, 5 showed a reduction of periportal infiltrate 
and only 2 remained low positive for liver HDAg expression. 
Furthermore, all patients with a reduction in periportal infiltrate in the post treatment 
biopsy (n = 5) had a decrease in AST level and no liver HDAg expression after treat-
ment. 
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Figure 1. liver HDAg expression before and after combination therapy with !FN/ACV. Open 
circles denote absence of HDAg. 
These 5 liver HDAg negative patients showed a decrease of periportal infiltrate and a 
decrease of serum AST level (4 normalised during therapy). In the other 5 patients, in 
whom liver HOAg remained low positive in the post treatment biopsy, severity of the 
periportal infiltrate remained stable or showed progression (fig 2). 
Most apparent is the relation between the absence of liver HDAg expression after 
treatment and the biochemical and histological improvement. 
HBeAg was positive in 2 out of 10 patients, 1 seroconverted to anti HBe after treat-
ment. None of the patients had HBcAg expression in the pre- or post treatment biopsy. 
16 - 52 weeks. 
A sustained normalisation of serum AST at 52 weeks follow-up was observed in 
patients no 6 and no 1 0. All other patients showed elevated AST levels as sign of liver 
ce!l inflammation, thus 3 patients relapsed after discontinuation of treatment. Patient no 
6 was HBcAg, HBeAg and HBV DNA negative prior to treatment and cleared HDAg in 
the post treatment biopsy. An AST peak occured immediately after treatment that 
normalised thereafter and remained normal with 2 years of follow-up (fig 3). Patient n° 
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Figure 2. Markers of liver cell inflammation {AST and periportal infiltrate) before and after 
IFN/ACV therapy. Note the decrease in inflammation in patients with absence of HDAg in the 
liver biopsy after treatment. 
5 showed no sign of active HBV replication and was antiHCV negative before treat-
ment. He cleared the HDAg from the liver, AST normalized during treatment and a 
marked reduction in periportal infiltrate was observed in the post treatment biopsy. 
Despite the absence of HDAg and HScAg in the liver, the liver disease reactivated with 
elevation of AST 3 months after stopping IFN administration (fig 4). 
DISCUSSION 
Sustained response to treatment in case of chronic hepatitis D defined as permanent 
absence of viral replication, normal serum transaminases and no signs of progressive 
liver disease was observed in 1 patient. This low frequency is similar to observations of 
others (2,3,4). Although the role of antiviral treatment cannot be proven in this single 
patient, a clear effect of therapy on liver HDAg expression was observed in 3 out of 8 
patients (38%). Complete suppression of liver HDAg was associated with diminished 
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Figure 3. AST levels of patient 6 before, during and after tFN/ACV therapy. A sustained remissi-
on followed antiviral therapy. The single elevated AST value after treatment remained unexplai-
ned. 
liver cell inflammation as assessed by serum AST and liver biopsy. These observations 
strongly suggest that antiviral treatment including IFN can be beneficial for patients 
with chronic hepatitis D. Results of combination therapy with IFN and ACV are not 
clearly different from those reported for IFN alone. 
The mechanism of action of IFN is still unclear. Since none of the patients had liver 
HBcAg expression, no evident HBV replication was present. The post treatment 
improvement was therefore more likely to be related to suppression of HDV than to 
suppression of HBV. This hypothesis is supported by the reactivation of the liver 
disease in antiHCV negative patients that were also negative for HBcAg in the post 
treatment biopsy. Why IFN, while sometimes completely suppressing HDAg expression, 
did not eliminate HDV is not clear. Like HBV, suppression of viral core antigen is fairly 
uniform but immune mediated cytolysis of viral!y infected hepatocytes apparently does 
not occur in responders to treatment. AST -peaks after 8 - 1 2 weeks of treatment, as 
sometimes observed in HBV infection (8), were not noticed. In cell culture experiments 
treatment with ribavirin abolished HDV RNA replication but HDV RNA apparently 
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Figure 4. Response to IFN/ACV therapy in a patient without HBV DNA and antiHCV. Note the 
relapse of liver disease 1 2 weeks after discontinuation of antiviral therapy. 
remained present since it recurred after withdrawal of 2-weeks drug treatment (9). 
Longterm suppression of HDV RNA may be required to allow elimination of HDV RNA 
by natural mechanisms. 
Chronic hepatitis D was observed in a heterogenous group of patients with various 
stages of the disease (mild fibrosis to cirrhosis). various degrees of HDV replication and 
- in intravenous drugabusers - associated hepatitis C virus infection. Heterogeneity for 
HBV in these patients was limited since all were negative for liver HBcAg. Also HiV 
was negative in all patients. 
Based on observations in this study, future evaluation of antiviral therapy in chronic 
hepatitis D probably should be limited to patients negative for HCV and HIV with 
stratification for HBV replication activity. The goal of induction therapy should be a 
repeated negative test for liver HDAg and HBcAg. Serum analysis for HDV RNA and 
HBV DNA as well as HDAg and HBeAg might be helpful! for defining the optimal time 
for performing the liverbiopsy. Maintainance therapy should be attempted, since 
reactivation occurs even in patients negative for liver HDAg and HBcAg. Future 
developments with PCR for HDV and HBV may help in defining endpoints for therapy. 
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CHAPTER 8 
SEVERE CHRONIC ACTIVE HEPATITIS (AUTOIMMUNE TYPE) MIMICKED BY COINFEC-
TION OF HEPATITIS C AND HUMAN IMMUNODEFICIENCY VIRUS 
The contents of this chapter have been excepted for publication in Gut under the same 
title and with the following authors: Luuk Berk, Solko W Schalm and Rudolf A Heijtink. 
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SUMMARY 
Severe chronic active hepatitis, defined as the presence of a five-fold elevation of 
serum aminotransferases in conjunction with a two-fold elevation of gammaglobulin for 
at least 1 0 weeks, is considered a progressive immunological liver disease requiring 
corticosteroid medication, particularly when serum autoantibodies and a marked 
lymphoplasmacellular periportal infiltrate in the liver biopsy are found. 
A case is described in which a 38-year-old male fullfilled the criteria for severe chronic 
active hepatitis. However his sex, his homosexuality and the presence of antibodies 
against human immunodeficiency virus led to the suspicion of a coinfection with 
hepatitis C virus rather than autoimmune disease. The rapid and complete response to 
alpha-interferon therapy and a recently available positive antibody test for hepatitis C 
virus indicate that a hepatitis C virus-related chronic active hepatitis, as illustrated by 
this case, can present as the severe autoimmune type of chronic active hepatitis. 
Moreover, as in hepatitis B, the response to therapy in hepatitis C virus-related severe 
chronic active hepatitis differs from that of autoimmune severe chronic active hepatitis. 
Keywords: alpha-lymphoblastoid-interferon, autoimmune type chronic active hepatitis 
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INTRODUCTION 
In 1968 severe chronic active hepatitis (CAH) was defined as an entity characterized by 
at least a 1 0-fold elevation of the serum aminotransferases levels for 1 0 weeks or a 
two-fold elevation of gammag!obulin together with a five-fold increase in serum 
aminotransferase levels (1 ). The disease, thought to be of autoimmune origin, usually 
progressed rapidly with a mortality rate of 50% in 2 years. Corticosteroid therapy was 
shown to increase life expectancy significantly (2,3,4). Subsequently the features of 
severe CAH were encountered in liver diseases of other etiology, such as primary biliary 
cirrhosis, primary sclerosing cholangitis, chronic hepatitis B infection (5,6,7}, and 
metabolic disorders requiring therapeutic modalities other than corticosteroids. The 
diagnosis of autoimmune severe CAH is based on the presence of CAH plus autoantibo-
dies in serum and portal and periportal lymphoplasmacellular infiltrates as well as 
piecemeal necrosis in the liver biopsy. 
The foflowing case suggests that chronic hepatitis C virus infection can mimic autoim-
mune severe CAH and that treatment with alpha-interferon (8) may induce clinical and 
biochemical remission in such patients. 
CASE-REPORT 
History 
A 38-year-old man, born in the Netherlands Antilles, was admitted for treatment of 
syphilis with intravenous penicillin. He had had a hepatitis 8 virus infection in the past 
as well as repeated gonococcal and Treponema pallidum infections; 1 year prior to 
admission he was found to be antiHIV- positive. Apart from a tonsillectomy at age 17 
and a perianal abscess and lobar pneumonia at age 37, there were no hospital admissi-
ons or surgical procedures in the patient's history. During admission elevated serum 
transaminase levels were found. Fatigue was his only symptom. There were no signs of 
alcohol abuse or intravenous drug abuse; he had never had a blood transfusion or 
undergone earpiercing or tattooing; there was no hepatitis in the family history; he took 
no medication. He was, however, a promiscuous homosexual. Physical examination 
revealed lymph node enlargement; liver and spleen were normal; apart from palmar 
erythema, there were no signs of chronic liver disease. Over a period of 26 weeks there 
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was a progression of hepatitis activity. Bilirubin concentration rose to 42 pmol/1 (normal 
less than 17), serum AST to 405 tU/l (normal less than 30), ALT to 300 IU/L (normal 
less than 30); serum albumin decreased from 34 to 28 g/1. Blood clotting tests 
remained normal: normotest 83%, fibrinogen 2.0 g/1, antithrombin m 86%. Alpha-
fetoprotein was below 3 pg/1. lgG was 72.5 g/1, lgM 4.8 g/!, lgA 2.4 g/1; anti-nuclear 
antibodies were positive (titer 1 :160J;anti-smoothmuscle antibodies and anti-mitochon-
drial were negative; anti-liver-kidney microsomal antibodies were not tested. Virus 
serological tests revealed the fo!lowing: HBsAg negative, antiHBs positive, antiHBc 
positive, antiHD {delta) negative, antiCMV-IgM negative, antiEB-VCA lgM negative and 
antiHIV positive. CD4 cell count was 0.6 x 1011/1 {600/mm3) and in vitro lymphocyte 
stimulation tests were normal. Ultrasound examination of the abdomen revealed a 
slightly enlarged liver ,and spleen. A liver biopsy showed probable cirrhosis (fig 1 A + 8) 
with CAH. The enlarged portal tracts and fibrous septa contained an extensive 
infiltrate, consisting of lymphocytes, plasma cells and some neutrophilic granulocytes. 
Piecemeal necrosis with severe degeneration of liver parenchyma and many Councilman 
bodies was seen (fig 1 8). 
Diagnosis and treatment 
According to the Mayo Clinic criteria (1,9) this patient had a severe CAH with immuno-
logical features. Immunosuppressive therapy appeared to be indicated. Because of the 
HIV infection and a suspected non-A,non-B hepatitis, corticosteroid therapy was 
postponed and a course of 5 MU alpha lymphoblastoid interferon (WeHcome Laborato-
ries, Beckenham, UK) subcutaneously daily was given (8). 
RESULTS 
Serum transaminases normalized in 2 weeks and serum lgG levels fell to less than 50% 
of the initial value (fig 2). When the dose of interferon was tapered to 2 MU every 
other day, the serum transaminase levels remained normaL Interferon was well-
tolerated, and the patient spontaneously reported the gradual disappearance of fatigue 
during treatment. The dose of IFN was increased to 2 MU daily at month 11 in an 
attempt to suppress HlV replication, since HIV-associated p24 antigen had become 
detectable in the serum. HIV p24 antigen became negative at month 13 only to 
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Figure 1. Liver biopsy showing disturbed architecture and fibrosis compatible with probable 
cirrhosis (x75J {A) and dense periportal lymphoplasmacellular infiltrate and piecemeal necrosis 
(x185) (8). 
reappear 2 months later. The patient rejected treatment with zidovudine and the dose 
of interferon was increased to 3 MU daily at month 20. At 22 months the patient 
withdrew from therapy. He felt physically well, and apart from an elevated serum lgG 
level, his liver disease was in biochemical remission. Bilirubin was 0.4 x ULN, serum 
aminotransferases 0.5 x ULN, albumin 39 g/1 and lgG 37.6 g/i. Anti-nuclear antibodies 
became negative. Clotting factors were 100%. No reactivation of his liver disease has 
been observed in 6 months of foHow·up. Serological testing for hepatitis C virus, 
available since month 28, showed the presence of antiHCV antibodies at the time of 
admission to our department, during treatment and at follow·up. 
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Figure 2. Serologic findings before, during and after alpha-interferon therapy in a 38-year-old 
male patient with severe CAH due to HCV and HlV coinfection. The dose of alpha-interferon 
was increased at month 11 and month 20 because of active HlV infection (see text). Note the 
rapid normalization of AST after start of therapy and the absence of relapse in the 6 months 
since discontinuation of alpha-interferon therapy. 
DISCUSSION 
The patient described in this report suffered from a severe CAH that presented 
serologically and histologicaHy as CAH of autoimmune origin. 
The diagnosis severe autoimmune CAH, however, depends on non-specific criteria such 
as a ten-fold increase in serum transaminase level, a two-fold increase in lgG leveL the 
presence of auto-antibodies and dense lymphoplasma cellular infiltrate in the liver. 
Since the patient was a promiscuous homosexual male, he was considered more likely 
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to have a viral disease than autoimmune type CAH. Chronic non-A,non-8 hepatitis was 
the most likely diagnosis and probably explained the elevated serum aminotransferase 
levels. The high lgG levels might be related to the HIV infection (1 0). The response to 2 
weeks of interferon treatment supported our suspicion of an HCV infection, later 
! 
virtually confirmed bY the detection of antiHCV antibodies. The confirmatory value of 
the finding of persistent anti-HCV reactivity in this patient with high serum lgG level 
however, should be questioned in view of the recent finding of the nonspecific 
reactivity of the antiHCV test in CAH. 
Prednisone treatment, probably life-saving in the event of severe autoimmune CAH, 
was no longer considered once the beneficial effect of lFN treatment was observed. 
Interestingly, persistent clinical and biochemical remission of the severe CAH occurred 
in this antiHlV positive patient after discontinuation of IFN treatment. Such a result is 
remarkable, since remission for 6 or more months of discontinuation of IFN therapy for 
chronic non-A,non-8 hepatitis occurs in the minority of patients (12) and supposedly 
reflects adequate immune controL 
This patient illustrates that diagnosis of severe CAH as the autoimmune type also 
requires the exclusion of HCV infection as well as of HBV and HDV infection, toxic 
hepatitis, metabolic disorders, primary biliary cirrhosis and primary sclerosing cholangi-
tis. In addition, this case supports the observation that chronic hepatitis C can be 
rapidly progressive in case of HIV coinfection. Still, such patients, as recently described 
by Martin et al (13), may be as responsive to JFN therapy as the usually milder form of 
hepatitis C virus infection. 
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CHAPTER 9 
RIFAMPICIN FOR CHRONIC HEPATITIS C WITH INCOMPLETE RESPONSE TO ALPHA· 
INTERFERON 

99 
SUMMARY 
Many patients with chronic hepatitis C on standard doses of alpha interferon (IFN) 
treatment experience only an incomplete normalization of serum aminotransferase 
levels. This situation may still lead to development of liver failure, aspecially in patients 
who do not tolerate higher doses of IFN. With the current knowledge of hepatitis C 
virus concerning its RNA genome and requirement of RNA dependent RNA polymerase 
activity for replication, combination therapy of IFN and an inhibitor of RNA synthesis 
could be beneficial. 
We treated a male hemophiliac with hepatitis C, liver cirrhosis and porta! hypertension, 
and an incomplete response to maximally tolerated doses of lFN, by administring 
additional rifampicin. Immediately after the start of rifampicin a normalization of serum 
aminotransferase levels occurred and biochemical remission persisted for more than six 
months after stopping rifampicin. ln the ensuing 2 years no progression of the liver 
disease was observed. 
This case suggests that rifampicin may have antiviral activity against hepatitis C. 
Definite proof of this effect of rifampicin can only come from measurement of serum 
HCV RNA levels. lf an inhibition can be demonstrated, the additional value of rifampicin 
in treating hepatitis C infection in incomplete responders to IFN should be evaluated in 
a controlled triaL 
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INTRODUCTION 
In the absence of a reliable test for measurement of HCV replication, the therapeutic 
aim is complete normalization of serum aminotransferases; as only after such a 
normalization improvement in liver histology has been documented. The cornerstone for 
treatment of chronic hepatitis C is alpha interferon (IFN). Still many patients experience 
an incomplete response to monotherapy with only partial reduction in serum transami-
nase levels (1 ,2,3). Available data on the virus replication strategy are insufficiently 
precise to design a combination schedule of drugs to suppress viral replication at 
several levels. However, the HCV is a member of the flavivirus family that require RNA 
dependent RNA polymerase activity for replication, in addition to cellular tRNA's for 
priming antigenomic RNA synthesis {4). Inhibition of this replication cycle logically 
occurs when a RNA polymerase inhibitor is administered. We therefore tested the 
effect of rifampicin (5) in a patient with chronic hepatitis C and an incomplete response 
to monotherapy with maximally tolerated doses of JFN. 
CASE HISTORY 
A 52 years old male hemophiliac developed hepatitis after administration of blood-pro-
ducts 6 years prior to admission to our department for progressive splenomegaly. He 
was working as an electromechanic engineer and appeared in good health. The only 
symptom was fatigue; he showed no signs of alcohol or drug abuse; he took no 
medication. Physical examination showed an enlarged spleen. Normal laboratory results 
were obtained for serum albumin and bilirubine; quick-test was 45 % (normal 65 - 135 
%}; platelet count was 92 * 109 /1 (normal 130 - 350 *109/1); ALT and AST were 
markedly elevated with respectively 209 and 166 U/1 (normal 30 U/1) a-foetoprotein 29 
pg/f. Serological tests for hepatitis 8, hepatitis D, cytomegalovirus, Epstein-Barr virus 
and human immuno deficiency virus or autoimmune disease were all negative. Ultraso-
nography showed an enlarged spleen of maximally 17 em and dilated portal veins. 
Esophageal X-ray showed moderately large varices. Liver histology showed an active 
cirrhosis with bile-duct proliferation and focal steatosis, compatible with hepatitis C. 
AntiHCV antibodies were present in the serum. In this patient with a child A liver 
cirrhosis due to hepatitis C, IFN treatment was initiated with a daily dose of 5 MU 
subcutaneously and tapered to 2.5 MU daily because of fatigue and malaise. 
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RESULTS 
Serum aspartate aminotransferase (AST) levels fell from 6-7 times the upper limit of 
normal to 3-4 times the upper limit of normal but decreased no further (fig). After 6 
months of lFN treatment rifampicin 4 x 150 mg was daily added orally to the IFN and 
the AST level rapidly fell to nearly normal. The dose of IFN was further reduced to 2.5 
MU every other day and after a period of 2.5 months with stable transaminase levels 
rifampicin administration was stopped. Normal serum transaminases persisted for 14 
months but after reduction of the lFN dose to 1 MU every other day, a flare-up of 
hepatocytoloysis occurred. With increment of the IFN dose to 2.5 MU 3 times a week 
normalization of aminotransferase levels occurred again and this dose wc.:s maintained 
for further treatment. 
DISCUSSION 
This case documents normalization of serum AST by IFN treatment with additional 
rifampicin administration. Normalization of AST levels in the setting of a progressive 
liver cirrhosis is considered to be important in view of our hypothesis that complete 
suppression of inflammatory activity may stop progression of the liver disease, even in 
case of cirrhosis (6). Increase of lFN doses may induce normalization of serum AST in 
patients with incomplete response to standard IFN therapy. However, increased doses 
of IFN are poorly tolerated for prolonged periods of administration, especialy in patients 
with liver cirrhosis. Rifampicin is a RNA polymerase inhibitor that could interfere with 
viral RNA synthesis either by inhibition of virus induced RNA dependent RNA polymera-
se or by inhibition of cellular tRNA synthesis required for priming new RNA genomes. 
The normalization of AST after rifampicin could have been due to an antiviral effect or 
increased clearance of aminotransferases by a non-specific enzyme induction. The 
persistence of the effect on serum AST after discontinuation of therapy suggests an 
antiviral effect rather than an enzyme induction. 
Recently ribavirin has also been shown to lower ALT level in chronic hepatitis C (7). 
Clearly the effect of these drugs on HCV RNA need to be determined before a choice 
can be made for more rational combination therapy. Eventually the efficacy of combina-
tion therapy versus 1FN monotherapy needs to be tested in a controlled trial. 
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The figure shows the serum AST level with an incomplete response to !FN therapy. Nearly 
normal serum levels of AST are obtained when rifampicin is added to the treatment regime. 
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Alpha-IFN is the cornerstone for treatment of chronic hepatitis 8, C and D. Inhibition of 
virus replication in chronic hepatitis 8 occurs in most patients during a-IFN treatment. 
Induction of virus latency after 16 weeks of therapy occurs in 25 % of patients 
(chapter 2). For chronic hepatitis C approximately 50 % of patients experience a 
decrease in hepatoce!lular cytolysis as a result of a-!FN treatment. Induction of HDV 
latency in chronica!ly infected patients during treatment, as measured by disappearance 
of liver HDAg expression, occurs in 35 % (chapter 7, 1 l and is not always associated 
with a decrease in hepatocyto!ysis. 
The physician treating patients with chronic viral hepatitis will be confronted with the 
foHowing problems: - nonresponse; -incomplete response ( = incomplete suppression of 
active virus replication, which nearly always leads to reactivation of replication activity 
after stopping interferon treatment); - and response followed by relapse to active virus 
replication in patients showing a response during therapy. Relapse reflects insufficient 
virus-specific immunity. The magnitude of these problems are summarized in the table. 
table 
MAGNITUDE OF RESPONSE FAILURES IN CHRONIC VIRAL HEPATITIS 
response relapse non response incomplete response 
HBV wild type 25% 10% 15% 60% 
HCV 50% 50% 20% 30% 
HDV 35% 90% 65% ? 
(H BV pre-core 70% 90% 30% ?I 
mutant 
This table summarizes the magnitude of response failures in the various forms of chronic viral 
hepatitis. 
In patients infected with the wild type HBV approximately half of the patients do not 
respond to therapy by a decline of serum HBeAg levels. Measurement of HBV DNA 
levels shows a significant decline in HBeAg-nonresponders. Therefore, only 10 to 15 % 
of patients are true nonresponders (chapter 3). Relapse of HBeAg-responders to active 
viral replication occurs as an unusual event and incomplete response remains as the 
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major problem to be dealt with. 
For chronic hepatitis C it is not yet established which virus parameters indicate a state 
of virus latency. For the time being response to therapy can only be identified by 
decreasing HCV RNA levels and/or decreasing aminotransferase levels. Definition of 
immunologic control depends on the relevance of HCV RNA negativity in serum and 
liver. The major clinical problems are incomplete response and relapse of serum 
transaminase elevation after interruption of treatment. 
In chronic hepatitis D, complete response cannot be differentiated from incomplete 
response with HDAg measurement in the liver, since patients negative for HDAg 
expression in hepatocytes showed both sustained response as well as reactivation to 
aminotransferase elevation. Relapse in chronic HDV infected patients is a frequent 
fenomenon (2). Immunologic control is a rare event in chronic HDV infection, probably 
because the only virus specific protein (HDAg) is expressed in the hepatocyte nucleus 
(3). Therefore, development of antiHBs antibodies seems the only possibility to obtain 
immunologic control over HDV infection {4); this appears to be a rare spontaneous 
event in chronically infected patients. The most frequent problems for the treatment of 
chronic hepatitis delta are nonresponse and relapse. 
Currently the inadequacies of therapy for chronic viral hepatitis are twofold: inadequate 
suppression of virus replication by a-lFN and inadequate induction of virus specific 
immunity. According to most investigators, virus specific immunity is difficult to induce 
in patients with chronic hepatitis D, C and the pre-core mutant (2,5,6). It usually 
follows however complete virus suppression in chronic wild type HBV infection and is 
characterized by HBe-seroconversion. 
This thesis focusses on various attempts to enhance virus suppression of a-IFN by 
combination with other antiviral agents. 
For HBV we investigated the synergistic effect of acyclovir (ACV) as a competitive 
inhibitor of HBV DNA polymerase or as a chain terminator of HBV DNA, but no increase 
in HBe-seroconversion rate was found. Zidovudine with a comparable mechanism as 
ACV, gave a modest inhibition of HBV DNA polymerase, suggesting this drug might 
give some additional virus suppression in a regime with a-IFN. However, considering 
the side effects of zidovudine, severe toxicity may occur during simultaneous administ-
ration of a-IFN. If zidovudine shows a significant effect on virus replication in a placebo 
controlled study, combination therapy with zidovudine and a-iFN may be evaluated. To 
avoid side effects of effective, but toxic drugs, such as zidovudine, an interesting 
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development is the targeting of drugs by conjugation to lactosaminated serum albumin 
(l-HSA). L-HSA has the capacity of binding to hepatocyte receptors and can release an 
antiviral drug into the target organ in a pharmacologically active form (7). Besides the 
concept of combination therapy for nonresponders and incomplete responders, 
improvement of treatment results can also be attempted by prolongation of a-lFN 
administration (chapter 2). Therapy for the pre-core mutant was not evaluated since 
this variety is rare in The Netherlands (8). 
limited experience with incomplete response of a patient with chronic HCV infection to 
a-lFN suggested an additional effect of rifampicin. If an effect of this RNA polymerase 
inhibitor can be demonstrated on HCV RNA levels, further evaluation in a controlled 
setting appears indicated. Ribavirin as a broad spectrum inhibitor of RNA virus replica-
tion may be another candidate to evaluate in a controlled setting (9). 
Combination therapy for chronic HDV infection was started because addition of ACV 
was believed to increase the chance of HBV elimination. As for chronic HBV, no 
additional effect of ACV was found in chronic HDV infection. The concept of treatment 
for chronic hepatitis D is to eradicate HBV infection, since HDV depends on HBsAg for 
cell-entry. Therefore monoclonal antibodies to HBsAg may block spread of HDV to 
neighbouring hepatocytes, which in time could eliminate the infection. 
The concept of combination therapy of a-lFN with nucleoside analogues for chronic 
viral hepatitis, as discussed in the various chapters, is applicable to nonresponders and 
incomplete responders to a-lFN monotherapy. However, the problem of relapse that 
especialiy occurs in chronic hepatitis C and D, requires enhancement of virus specific 
immunity. Recent studies with interleukin 1-13., interleukin 2 and tumor necrosis factor 
indicate that virus specific immunity may be enhanced by these immunomodulators 
(1 0,11 ). Future studies are needed to assess whether prolongation of a-lFN monothera-
py, combination therapy of a-IFN with nucleoside analogues and immunomodulatory 
therapy with other biological response modifiers than a-IFN will result in safe and 
effective therapies for chronic viral hepatitis. 
In the history of treatment of hepatitis, empirics have led to intriguing proposals for 
therapy in ancient times. We should bear in mind that even in modern medicine 
empirical learning processes dominate the treatment of chronic viral hepatitis. Sophisti-
cated laboratory methods allowed insight in the replication cycle of the viruses with the 
development of rational treatment regimes, but "trial and error" learn the clinician 
whether the therapy works. 
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SUMMARY 
Chapter 1 presents the history of hepatitis treatment. Although only indirect evidence 
exists, viral hepatitis may exist for several thousands of years. Therapy has been 
symptomatic until recently the development of molecular biology atlowed to design a 
rational therapy aimed at eradication of the viruses causing hepatitis. Current ideas 
about replication of HBV, HCV and HDV are discussed with possible therapeutic targets 
in the replication cycle. Finally the aims of the studies are outlined. 
The thesis focusses mainly on improvement of the antiviral effects of a~lFN by 
combination with potentially synergistic drugs. The first study (chapter 2) describes the 
effect of 4 months of treatment with a-lFN in combination with 2 2-week courses of 
ACV on HBe-seroconversion in chronic hepatitis B. In a randomized controlled study 
this treatment resulted in a slightly higher HBe-seroconversion compared to untreated 
control patients. Quantitative HBeAg measurement showed a significant decrease of 
HBeAg titer and separate analysis of HBeAg-responders, partial HBeAg-responders and 
HBeAg-nonresponders in the treatment group suggested that prolongation of therapy 
may yield more HBe-seroconverters. No additional effect of ACV was found. 
The second study was performed to evaluate the additional effect of HBV DNA 
measurement during antiviral therapy for chronic hepatitis B (chapter 3). Quantitative 
HBeAg and HBV DNA measurements in the therapy group of the previously reported 
study showed that quantitative HBeAg measurement can be used to monitor antiviral 
therapy and determine endpoint of treatment. HBV DNA levels were of additional value 
to identify response in patients with high levels of viral replication activity. 
Patients on a-tFN treatment may suffer serious influenza-like side effects that can be 
countered largely by non-steroidal-anti-inflammatory drugs. Therefore, the influence of 
paracetamol and indomethacin on a-IFN effects was investigated (chapter 4). Satisfac-
tory control of side effects was obtained without a demonstrable negative effect on 
inhibition of viral replication (HBV DNA polymerase activity) nor on the elevation HLA 
class I turnover (beta 2 microglobulin level). 
Since the additional effect of ACV on HBe-seroconversion could not be demonstrated, 
the effect of zidovudine on HBV replication was investigated in an uncontrolled setting. 
A moderate decrease in DNA polymerase activity was found with a dose response 
effect that allows further evaluation. Because of the toxicity of zidovudine a report in 
the Lancet about HBs-seroconversion induced by the herb Phyllanthus Amarus, 
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appeared interesting to be investigated in our patient population. A small double blind 
cross-over study was designed that showed no effect of the herb on serum levels of 
HSsAg, HBeAg or HBV DNA (chapter 6). 
The effect of ACV and a-lFN combination treatment was also investigated in chronic 
hepatitis type D (chapter 7). This therapy that was aimed at eradication of the HSV 
coinfection that is obligatory for HDV infection, showed a marked decrease in liver 
HDAg expression and serum aminotransferase levels during treatment. However, 
reactivation of liver disease occurred after interruption of therapy in all but one patient. 
No additional effect of ACV was found. 
Chapter 8 reports on the treatment of a patient with a severe chronic active hepatitis, 
occurring as an auto~immune type hepatitis. A combined HIV and HCV infection 
appeared to be responsible for this disease. Although prednisone treatment has been 
reported to be life~saving in case of a severe chronic active auto-immune type hepatitis, 
this case clearly belonged to a sub-group of patients in which prednisone therapy is 
contra-indicated. Alpha-JFN therapy resulted in normalization of serum AST level and 
restoration of the liver-function with sustained success after interruption of therapy two 
years later. 
Another case of chronic hepatitis C is described in chapter 9. Combination therapy with 
rifampicin and a~IFN was started because of a poor reaction on a-IFN monotherapy. An 
additional effect of rifampicin was suggested with normalization of serum AST level. 
Since rifampicin as a RNA polymerase inhibitor may be effective in the treatment of 
hepatitis C, this drug should be tested for its effect on serum HCV RNA levels. 
In the discussion (chapter 1 Ol the problems concerning antiviral therapy for chronic 
viral hepatitis are outlined and the implicatons for future treatment strategies are 
discussed. 
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SAMENVATTING 
Hoofdstuk 1 beschrijft de geschiedenis van de behandeling van virale hepatitis. Er 
bestaan aanwijzingen dat virale hepatitis reeds vele duizenden jaren bestaat. Behande-
ling van geelzucht was symptomatisch, tot in de twintigste eeuw de ontwikkeling van 
molecu!air biologische technieken de herkenning van virale verwekkers mogelijk maakte. 
De huidige therapie is gericht op het klaren van deze verwekkers en het verkrijgen van 
immunologische centrale over de infectie. Huidige inzichten in de vermenigvuldiging van 
HBV, HCV en HDV worden besproken, samen met de mogelijke therapie doelwitten in 
de vermenigvuldigingscyclus van deze virussen. Tenslotte worden de doelstellingen van 
de studies geformuleerd. 
Alta-interferon {a-IFNJ wordt beschouwd als basis bestanddeel van elke behandeling 
van chronische virale hepatitis. Deze dissertatie behandelt overwegend de mogelijke 
verbetering van de standaard therapie met a-IFN. 
De eerste studie (hoofdstuk 2) beschrijft de behandeling van combinatie therapie van a-
IFN met acyclovir (ACVJ voor chronische HBeAg positieve hepatitis. B. Tijdens een 
gerandomizeerd, gecontroleerd onderzoek trad een HBe-seroconversie op in vijfentwin-
tig procent van de therapie patienten en in veertien procent van de onbehandelde 
contro!e patienten. Kwantitatieve analyse van serum HBeAg spiegels toonde een 
significante daling in de therapie groep in vergelijking met de controle groep. Verder 
bleek uit subgroep analyse van responders, partii:He responders en nonresponders uit de 
therapie groep dat verlenging van de therapie duur tot een hager percentage HBe-
seroconversie zou kunnen leiden. Een additioneel effect van ACV kon niet worden 
aangetoond. 
In hoofdstuk 3 wordt de waarde van een kwantitatieve HBeAg bepaling vergeleken met 
de waarde van een kwantitatieve HBV DNA standaard test. Deze vergelijking toont aan, 
dat in het merendeei van de patienten een kwantitatieve HBeAg bepaling voldoende is 
om therapie resultaten te vervolgen en het eindpunt van de behandeling vast te stellen. 
Additionele HBV DNA meting is nodig om in patii~nten met hoge activiteit aan virale 
vermenigvulding, bij uitblijven van een daling van het serum HBeAg, tach een respons 
op de therapie te kunnen vaststellen. 
Omdat patienten hevige griepachtige bijwerkingen kunnen vertonen bij het instellen van 
de behandeling met a-!FN, werd het effect van paracetamol en indomethacine op 
bijwerkingen en antivirale effecten van a-!FN bestudeerd (hoofdstuk 4). lndomethacine 
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en paracetamol werden met succes toegediend om griepachtige verschijnselen van a-
IFN te voorkomen. Er kon desondanks een significante ramming van a-IFN op virus 
vermenigvuldiging (serum HBV DNA polymerase activiteitl en op HLA klasse I turnover 
(beta 2 microglobuline concentratiel worden vastgesteld. Geconcludeerd werd dat 
indomethacine en paracetamo! goed de initiSle bijwerkingen van a-JFN konden voorko-
men zonder aantoonbaar negatief effect op de antivirale werking van a-IFN. 
Vanwege het teleurstellende effect van ACV toevoeging aan de a-IFN therapie werd de 
werking van zidovudine op HBV replicatie onderzocht (hoofdstuk 5). Naast een matige 
remming van serum HBV DNA polymerase activiteit, duidde toediening van verschiflen-
de doseringen AZT op een mogelijk dose-response effect. Deze studie lijkt verder 
onderzoek naar zidovudine als HBV DNA replicatie remmer te rechtvaardigen in een 
gecontroleerde opzet. 
Vanwege de toxiciteit van zidovudine was het aantrekkelijk om een niet toxisch 
plantaardig geneesmiddel (Phyllanthus amarus) te onderzoeken, waarvan een hoge mate 
van HBs-seroconversie beschreven was. Er werd een kleine gecontroleerde studie 
gedaan met een cross-over opzet (hoofdstuk 6). Helaas werd geen effect op serum 
spiegels van HBsAg, HBeAg of HBV DNA waargenomen, hetgeen ook door andere 
onderzoekers werd bevestigd. 
Een combinatie therapie van a-IFN en ACV werd ook voor chronische hepatitis D onder-
zocht metals doel de HBV infectie te elimineren (hoofdstuk 7). Delta antigeen expressie 
in de lever en serum AST spiegels toonden een daling gedurende de behandeling, maar 
reactivatie van de hepatitis werd gezien na onderbreken van de therapie. Er werd geen 
extra effect van ACV waargenomen. 
Hoofdstuk 8 beschrijft de behandeling van een patient met een ernstige chronisch 
actieve hepatitis die zich presenteerde als een auto-immuun hepatitis. Een HIV en HCV 
coinfectie, die goed reageerde op behandeling met a-JFN in p!aats van met prednison 
zoals gebruike!ijk is bij ernstige auto-immuun hepatitis, bleek aan dit ziektebeeld ten 
grondslag te liggen. 
Behandeling van een patient met chronische hepatitis C met de combinatie a-IFN en 
rifampicine wordt beschreven in hoofdstuk 9. Toevoeging van rifampicine als RNA 
polymerase inhibitor aan de bestaande a-IFN therapie werd gedaan vanwege onvoldoen-
de respons de op a-JFN monotherapie. De serum transaminasen normaliseerden na start 
van de rifampicine zodat een additief effect veronderste!d werd wat verder onderzocht 
zal moeten worden met behulp van serum HCV RNA bepalingen. 
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Het laatste hoofdstuk bespreekt de problemen rand de behandeling van chronische 
vira!e hepatitis. Suggesties voor toekomstige behande!ingen worden besproken. 
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